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Complex Regional Pain Syndrome (CRPS) is defined by the International Association for 
the Study Pain (IASP) as a “syndrome characterized by a continuing (spontaneous and/
or evoked) regional pain that is seemingly disproportionate in time or degree to the usual 
course of pain after trauma or other lesion. The pain is regional (not in a specific nerve 
territory or dermatome) and usually has a distal predominance of abnormal sensory, motor, 
sudomotor, vasomotor, edema, and/or trophic findings. The syndrome shows variable pro-
gression over time. CRPS type I develops after any type of trauma, especially fracture, soft 
tissue lesion. CRPS type II occurs after major nerve damage” (1). CRPS is considered to be a 
rare syndrome with an estimated incidence ranging from 5.5-26.2 per 100.000 person-years 
(2, 3). Despite the rareness of this syndrome, research into this syndrome is important as, if 
left untreated, this syndrome can lead to a debilitating loss of function of the affected limb 
and can also have a significant social impact on the life of patients (4).
CRPS is arguably one of the most controversial diagnoses of our time. This is due to two 
main factors: 1) a common denominator in the pathophysiology has not yet been identified, 
and 2) there are no diagnostic tests yet to objectively diagnose this syndrome. The history of 
CRPS has therefore been turbulent and is characterized by numerous changes to the name 
of this syndrome, the clinical criteria to diagnose this syndrome (5), and the treatment of 
this syndrome.
Further, the lack of a common pathophysiological denominator and the lack of objective 
diagnostic tests lead to skepticism among physicians on the existence of this syndrome (6, 
7), despite extensive empirical evidence proving otherwise. The consequence is a negative 
impact on the patient, starting with a delay in diagnosis, a delay in initiation of appropriate 
therapy, and a general lack of acknowledgement and awareness of the patient’s illness. Thus, 
it is important that research on CRPS focusses on further advancing our understanding 
on the pathophysiology of this syndrome and with this, exploring possible objective tests 
that may aid in the diagnosis and management of this syndrome. To this end, clinical and 
biochemical  biomarkers are an interesting topic of research.
At present, it is widely accepted that CRPS has a multi-mechanism pathophysiology 
and that treatment of this syndrome should target the multiple mechanisms that may play a 
role in each CRPS case (8). Due to this multi-mechanism pathophysiology, it is likely that 
there will never be one diagnostic test or biomarker specific for CRPS, rather there may be a 
panel or combination of tests or biomarkers that will be used, with each test and biomarker 
reflecting a different pathophysiological mechanism.
In this thesis, we have chosen to focus on one of the most important pathophysiological 
mechanisms in CRPS, i.e. inflammation, and the biomarkers related to this inflammatory 
process. Inflammation plays a role both in the initiation and maintenance of CRPS. Three 
main sources of inflammation have been identified in CRPS: neurogenic inflammation, 
neuroinflammation and dysregulation of the immune system. Each of these sources can be 







therapies. In this thesis, we focus on biomarkers that reflect dysregulation of the immune 
system in CRPS.
A biomarker is defined as “a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic responses 
to a therapeutic intervention” (9). Building on this definition, a biomarker can also be used 
in the diagnosis, prognosis and monitoring of activity and/or severity of a disease (9). For 
CRPS, various potential biomarkers of inflammation have been identified, however, none 
of these markers have yet been validated in terms of use in diagnosis, monitoring of disease 
activity and/or severity, and effect of therapy.
Inflammatory biomarkers in CRPS can be both clinical and biochemical in nature. 
Clinical biomarkers of inflammation are, for example, pain, redness, swelling, warmth and 
loss of function of the affected limb, i.e., the classical signs of inflammation. Biochemical 
biomarkers of inflammation can be measured in various fluids and can range from cytokines 
to microRNAs (miRNAs) (10, 11). The crux in CPRS is, however, that while increased levels 
of various potential biochemical biomarkers have been identified, there is often a discrepancy 
between clinical findings and expected biochemical findings and vice versa. A prominent 
example is that levels of classic inflammatory markers such as C-reactive protein (CRP) and 
white blood cell count (WBC) are not increased in patients with acute CRPS (12), a phase in 
which classic signs of inflammation are often seen (2, 13-15). Another example is the finding 
that in patients with chronic (cold) CRPS in which inflammation is clinically not present, 
there still may be biochemical evidence of an inflammatory process (16).
Our group have previously studied various local (i.e., in the affected limb) and systemic 
(i.e., in venous blood) markers of inflammation in CRPS. Locally, in skin blister fluid, our 
group previously found significantly higher levels of the pro-inflammatory cytokines tumor 
necrosis factor(TNF)- α and Interleukin(IL)-6, however, these cytokines were not associated 
with clinical symptoms and signs of impairment (17). In a follow-up study in the same 
patient sample, our group assessed the levels of these pro-inflammatory cytokines in the 
CRPS patients who could then be considered to have intermediate stage CRPS (1-2 years 
after the initial event), hypothesizing that local inflammation would only be present during 
the initial, acute phase of disease, and that the production of pro-inflammatory media-
tors would decrease during the course of disease (18). We found that although there was 
improvement in clinical symptoms and signs, this improvement was not reflected biochemi-
cally in a reduction of TNF-α and IL-6 in blister fluid of the affected and contralateral limb. 
The levels of these pro-inflammatory cytokines remained higher in the affected limb than 
in the contralateral limb and there was no difference between levels of these cytokines at 
follow-up versus baseline (18). In a further follow-up study in 12 CRPS patients from whom 
data was available at a median disease duration of 4 months, 3 years and 6 years, our group 
found that the level of these pro-inflammatory cytokines were significantly higher in the 












this difference had diminished at 6 years follow-up. Importantly, no correlation was found 
between the pro-inflammatory cytokines and clinical characteristics such as pain and differ-
ences between affected and contralateral limb for temperature, volume and mobility (19). 
Although these findings show that blister fluid TNF-α and IL-6 may not be appropriate 
biomarkers for monitoring disease severity, there may still be a role for these markers in, for 
example, monitoring effects of therapy with TNF-α inhibitors at a biochemical level (20, 
21). These biomarkers have yet to be validated for this use.
Systemically, our group previously assessed the role of autoantibodies in CRPS (22). 
We found that the prevalence of anti-nuclear antibodies (ANAs) was significantly higher 
in CRPS patients (30%) than in the healthy population (4%) (22). Again, no difference 
in prevalence of these autoantibodies could be found for available clinical characteristics 
such as warm versus cold CRPS, nor was there a difference in disease duration in CRPS 
patients with a positive ANA test versus patients with a negative ANA test. In addition, our 
group noted that the prevalence of ANAs in CRPS patients was closer to the prevalence of 
an autoimmune disease such as rheumatoid arthritis (RA, 25%), which is thought to have 
auto-inflammatory subtypes, than the prevalence of ANAs in a classic systemic autoimmune 
disease such as systemic lupus erythematosus (SLE, >99%) (23-26). Apart from concluding 
that there may be a role for autoantibodies in the pathophysiology of CRPS (22, 27, 28), 
studies on autoantibodies still cannot conclude whether these autoantibodies are pathogenic 
or a result of the inflammatory process in CRPS. Furthermore, treatment with a 6-week 
low-dose Intravenous Immunoglobulin (IVIG) infusion did not result in significant pain 
relief in patients with moderate to severe CRPS (29). This made us question the role of 
autoantibodies in CRPS and our focus shifted from autoantibodies to T-cells and monocytes 
and macrophages in CRPS. T-cells because these cells, together with B-cells, are the most 
crucial cells of the adaptive immune system, and monocytes and macrophages, because find-
ings such as higher blister fluid levels of TNF-α and IL-6, which are primarily produced by 
pro-inflammatory M1 macrophages, point towards a dysregulated innate immune response 
in CRPS. In addition, therapies such as prednisolone and thalidomide (TNF-α inhibitor) 
which exert their effects mainly on T-cells and monocytes, respectively, seem to be effective 
in certain subgroups of CRPS patients (30-34).
We therefore chose to study the activation of T-cells and the monocyte-macrophage sys-
tem in CRPS using two biomarkers: the soluble interleukin-2 receptor (sIL-2R) which is a 
marker for T-cell activation (35) and soluble CD163 (sCD163) which is a marker indicating 
activation of local tissue-resident macrophages, and thus the monocyte-macrophage system 
(36). Until now, both markers had not been measured or applied as potential diagnostic/
therapeutic markers in CRPS. The sIL-2R is already clinically applied to monitor disease 
activity and/or severity in diseases where T-cell activation is centrally involved, such as 
rheumatoid arthritis and sarcoidosis (35, 37-40). In addition, a recent retrospective cohort 







with a high sensitivity  (88%) and specificity (85%) (41). Soluble CD163 is a relatively new 
marker (42). Its use as a biomarker, be it diagnostic or prognostic, has been established for 
certain inflammatory diseases such as haemophagocytic syndrome (diagnostic and prognos-
tic), sepsis (prognostic), systemic sclerosis (prognostic) and HIV (prognostic) (43). Further, 
sCD163 is increased in the serum of patients with chronic inflammatory disorders such as 
rheumatic diseases, psoriasis and obesity (43-45).
A big advantage is that both markers can easily be measured in venous blood using a 
validated ELISA system. Therefore, if these markers prove to be valuable in the diagnosis 
and/or prognosis and/or monitoring of effect of therapies in CRPS, they could be easily 
implemented in clinical practice.
ReLevaNCe of thIS ReSeaRCh
This thesis further builds on previously established hypotheses of inflammation in CRPS 
and expands our current knowledge on the (inflammatory) pathophysiology of CRPS. 
Furthermore, the application of two new potential biomarkers for the diagnosis and/or 
management of CRPS is explored.
Ultimately, the goal of this thesis is to emphasize the importance of biomarker research in 
CRPS by exploring the role of biomarkers of inflammatory pathogenesis in CRPS, thereby 
introducing more objectivity to the clinical diagnostic process and reducing subjectivity, and 
skepticism, surrounding the diagnosis CRPS.
aIm aND outLINe of thIS theSIS
The aim of this thesis was threefold: 1) to explore the need for diagnostic and therapeutic 
biomarkers in CRPS; 2) to study the role of the T-cell-specific sIL-2R and macrophage-
specific sCD163 as potential biomarkers in CRPS; and 3) to address (recent) concerns that 
CRPS is not a distinct diagnostic entity.
To this end, we divided this thesis into three parts. Part 1 kicks off this thesis with the 
introduction (Chapter 1) followed by a concise article on the pathophysiology, diagnosis and 
management of CRPS (Chapter 2). This is followed by a review article on the importance 
of biomarkers, especially biomarkers of inflammation, in the diagnosis and management of 
CRPS (Chapter 3). Part 2 further elaborates on this need for biomarkers in CRPS through 
hands-on investigation of two potential biomarkers. The first study in part 2 investigates 
whether sIL-2R levels are increased in CRPS (Chapter 4). This is followed by a study that 
investigates whether sIL-2R can be used as a diagnostic biomarker in CRPS (Chapter 5). 












activation marker sCD163 is increased in CRPS patients (Chapter 6). Finally, in Part 3, 
arguments presented in the literature that CRPS is not a distinct diagnostic entity are ad-
dressed and refuted in a review article using the extensive empirical literature on CRPS 
(Chapter 7). Part 3 then ends with the discussion in which findings from the articles in this 
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Complex regional pain syndrome (CRPS) is a post-traumatic disorder characterized by a 
non-dermatomal distributed, severe, continuous pain in the affected limb and is associated 
with sensory, motor, vasomotor, sudomotor and trophic disturbances.
CRPS is a clinical diagnosis and is diagnosed using the new International Association for 
the Study of Pain (IASP) clinical diagnostic criteria. There is no diagnostic test specific for 
CRPS.
The pathophysiology of CRPS is multifactorial, with recent studies pointing towards CRPS 
being an exaggerated inflammatory response as a result of trauma or surgery.
CRPS should be treated in a multidisciplinary fashion with treatment consisting of adequate 
pain management, physiotherapy and psychological evaluation and intervention.
































Complex regional pain syndrome (CRPS) is a clinical disorder that is characterized by 
severe, continuous pain in the affected extremity, which is accompanied by sensory, vasomo-
tor, sudomotor/edema and motor/trophic changes (1). The pain is regionally restricted (i.e. 
cannot be related to a specific dermatome) and disproportionate to the inciting event (1, 2).
CRPS is usually precipitated by trauma (mostly fractures) or surgery (2, 3). The upper 
extremity is affected more often than the lower extremity  (2-4). CRPS is usually limited to 
one extremity, however cases of CRPS in multiple extremities have been described (2).
The incidence of CRPS has been reported to range from 5,5 to 26,2 per 100.000 person 
years (3, 5). Women are more frequently affected than men with studies reporting a three 
to fourfold higher incidence in women (3, 5). The highest incidence was found in women 
aged 61-70 (3).
Two distinctive forms of CRPS are currently described in the literature. CRPS type I 
where there is no demonstrable nerve lesion and CRPS type II where there is demonstrable 
nerve lesion (1, 4, 6). CRPS type I and II do not differ in clinical presentation and choice of 
treatment (7). Consequently, CRPS will be used as a general term in this article referring to 
both CRPS type I and CRPS type II.
CRPS can have a severe impact on the quality of life of patients and can lead to sub-
stantial physical as well as social disability (8, 9). It is therefore important for clinicians to 
recognize and diagnose this disorder in order to provide appropriate care and guidance to 
patients suffering from this debilitating disease.
The purpose of this educational article is to provide clinicians with concise information 
regarding the pathophysiology, diagnosis and treatment of CRPS.
CLINICaL PReSeNtatIoN
Patients generally present themselves with severe, continuous pain that typically takes on a 
glove- or stocking like distribution (2, 3). Injury or surgery usually precede the symptoms(2, 
3).
The pain is often accompanied by sensory, vasomotor, sudomotor/edema and motor/
trophic symptoms. These signs and symptoms can vary during the course of the disease.
Patients may report (hyper) sensitivity to painful as well as non-painful stimuli (hy-
peraesthesia and/or allodynia). Differences in skin temperature between the affected and 
contralateral limb may be reported.
Sweating patterns between the affected and contralateral limb may be altered. Swelling 
of the affected limb can be reported. Symptoms of motor dysfunction such as loss of range 







and nail growth of the affected limb (2, 3). Patients may further report increase of symptoms 
after exercise(2).
Findings during physical examination include, but are not limited to, allodynia and/or 
hyperalgesia, differences in color and skin temperature between the affected and contralateral 
limb and edema of the affected limb (2, 3). Functional tests may reveal a reduction in the 
range of motion of the affected limb in comparison with the contralateral limb (3). Tremor, 
dystonia, and altered nail and hair growth of the affected limb can also be observed(2, 3).
CRPS patients are often described as having warm, intermediate or cold CRPS based on 
reported and measured skin temperature differences between the affected and contralateral 
limb(2, 10).
Current research suggests the existence of different phenotypes of CRPS based on the 
signs and symptoms deemed most prominent during history taking and physical examination 
(11). These signs and symptoms could reflect the underlying pathophysiological mechanism 
(i.e. inflammation, pain/sensory disturbances, vasomotor disturbances, motor disturbances 
and psychological disturbances). When assessing signs and symptoms of CRPS patients, 
it is important for physicians to recognize which pathophysiological mechanism is most 
prominent. By determining the most prominent mechanism, physicians can use specific 
therapies to target these mechanisms (Figure 1).
It is our hypothesis that in the majority of patients, especially patients with warm (acute) 
CRPS, inflammation is the most prominent mechanism. All the other mechanisms are a 
result of the ongoing inflammation. During the course of the disease, inflammation disap-
pears in a part of the patients, resulting in different forms of rest damage.
DIaGNoSIS
There is currently no gold standard for the diagnosis and treatment of CRPS. History and 
physical examination are the cornerstones for appropriate diagnosis and management (1).
Various criteria exist for the diagnosis of CRPS (1, 2). Currently, the most commonly 
used criteria for the diagnosis of CRPS are the new International Association for the Study 
of Pain (IASP) clinical diagnostic criteria (1) (Table 1).  These criteria are based on observed 
and patient-reported signs and symptoms (1).
CRPS has an extensive differential diagnosis, which can be summed up into the follow-
ing categories: neuropathic pain-like syndromes, myofascial pain syndromes, inflammation, 
vascular diseases and psychological disorders (Table 2) (4). Most of these disorders have 
similar presentations, occasionally making the diagnosis of CRPS a challenge.
As the pathophysiology of CRPS is still not completely understood, there is limited 
use for additional clinical and laboratory tests in the diagnosis of CRPS (4). Diagnostic 






























and symptoms or to monitor the signs and symptoms of CRPS. An example of the latter 
is quantitative sensory testing, which is mostly used in research settings to quantify sensory 
disturbances found during physical examination.
PathoPhySIoLoGy of CRPS
Th e exact pathophysiology of CRPS is still unknown (12). Both peripheral and central 
mechanisms are thought to play a role in the initiation and maintenance of CRPS (12).
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Various studies point towards CRPS being an exaggerated inflammatory response as a result 
of trauma or surgery (2, 13). This inflammatory response has long been a topic of debate, as 
general markers of inflammation such as C-reactive protein (CRP), white blood cell count, 
interleukin-6 (IL-6) and erythrocyte sedimentation rate (ESR) are usually not elevated in 
plasma of CRPS patients (2, 14).  However, when considering the symptoms of (acute) 
CRPS, ‘classic signs of inflammation’ such as pain, redness, increase in temperature, swell-
ing, and loss of function, are often displayed(8).
Recent studies focusing on inflammatory processes in CRPS have found higher levels 
of pro-inflammatory cytokines in blister fluid (IL-6, tumor necrosis factor-α (TNF-α)) of 
the affected extremity compared with the unaffected extremity. This suggests a role for local 
inflammatory processes in CRPS (13). Elevated levels of pro-inflammatory cytokines have 
further been found in serum, plasma, and cerebrospinal fluid of patients with CRPS (14-16).
Pro-inflammatory cytokines have been suggested to be involved in peripheral nociceptor 
activation and sensitization, which in turn could cause symptoms such as pain and hyperal-
gesia that are experienced in CRPS(17).
Neurogenic inflammation in CRPS
Apart from the ‘classic’ form of inflammation, studies have proposed neurogenic inflamma-
tion as an underlying mechanism for symptoms such as edema, vasodilation, and increased 
table 1 New International Association for the Study of Pain (IASP) clinical diagnostic criteria for 
CRPS (1)
1. Continuing pain, which is disproportionate to any inciting event.
2. Must report at least one symptom in three of the four of the following categories: 
- Sensory: reports of hyperaesthesia and/or allodynia 
-  Vasomotor: reports of temperature asymmetry and/or skin color changes and/or skin color 
asymmetry 
- Sudomotor/oedema: reports of oedema and/or sweating changes and/or sweating asymmetry 
-  Motor/trophic: reports of decreased range of motion and/or motor dysfunction (weakness, 
tremor, dystonia) and/or trophic changes (hair, nail, skin) 
3. Must display at least one sign at time of evaluation in two or more of the following categories: 
-  Sensory: evidence of hyperalgesia (to pinprick) and or allodynia (to light touch and/or deep 
somatic pressure and/or joint movement) 
- Vasomotor: evidence of temperature asymmetry and/or skin color changes and/or asymmetry 
- Sudomotor/oedema: evidence of oedema and/or sweating changes and/or sweating asymmetry 
-  Motor/trophic: evidence of decreased range of motion and/or motor dysfunction (weakness, 
tremor, dystonia) and/or trophic changes (hair, nail skin) 






























sweating that are observed in CRPS (18). Studies have found increased levels of calcitonin-
gene-related peptide (CGRP) and substance P (SP) in serum of patients with CRPS versus 
healthy controls (14, 18). These neuropeptides have been shown to lead to neurogenic 
dilatation of arterioles (CGRP) and plasma protein extravasation (SP)(19). This in turn 
could explain the redness and swelling that are observed in CRPS (18, 19).
table 2 Differential diagnosis of complex regional pain syndrome. Taken from van Eijs et al.,  Evi-
dence-based Interventional Pain Practice: According to Clinical Diagnosis. 16. Complex Regional Pain 
Syndrome(4). Published by John Wiley & Sons, Ltd.  Copyright © 2012 John Wiley & Sons, Ltd.
Neuropathic pain syndromes




o De-afferentation pain post-cerebrovascular accident
o Plexopathy 

















o Repetitive strain injury
o Fibromyalgia
Psychiatric problems








CRPS as an autoimmune disease
CRPS has previously been described as an autoantibody-mediated autoimmune disease (20, 
21). Passive transfer of CRPS patient serum-immunoglobulin G has been shown to induce 
behavioral changes in mice, and serum from CRPS patients has been shown to stain rodent 
sympathetic ganglia (20, 22). Furthermore, a small group of CRPS patients experienced pain 
relief after treatment with low-dose intravenous immunoglobulin (21). A study conducted 
by Dirckx et al. showed a significantly higher proportion of CRPS patients with positive 
anti-nuclear antibody test results as compared to a population of healthy blood bank donors 
(23).  There are thus many findings supporting this theory of auto-immunity(20, 23).
However,  to define a disease as an autoimmune disorder certain criteria (Witebsky’s 
criteria) must be met (24). These criteria have not yet been fulfilled in the case of CRPS 
which gives rise to the question whether CRPS is more an auto-inflammatory than an auto-
immune disease(23).
Deep-tissue microvascular ischemia-reperfusion injury in CRPS
Another hypothesis on the pathophysiology of CRPS is that of deep-tissue microvascular 
ischemia-reperfusion injury (25). This hypothesis, which was tested in a chronic post-isch-
aemia pain animal model, proposes a state of deep-tissue ischemia and inflammation caused 
by a microvascular ischaemia-reperfusion injury as the cause for abnormal pain sensations 
such as allodynia in CRPS (25, 26).
Genetics and CRPS
Genetics seem to play a role in the predisposition to CRPS. A Dutch cohort study showed 
the frequency of human leukocyte antigen (HLA)-DQ1 to be significantly higher in CRPS 
patients than in the controls (27). There is evidence that HLA-B62 and HLA-DQ8 are 
associated with CRPS with fixed dystonia (28). Another study showed HLA-DR13 to be as-
sociated with multifocal or generalized tonic dystonia of CRPS (29). These findings indicate 
that certain HLA loci may be involved in the susceptibility to certain phenotypes of CRPS 
(28, 29).
Cortical reorganization in CRPS
Central processes, such as cortical reorganization and changes in pain processing, may also 
play a role in CRPS (30-33). Cortical reorganization has been shown to take place in both 
the primary somatosensory cortex (S1) and the motor cortex (30, 32). Maihofner et al. 
showed changes in S1 to be correlated with the intensity of pain and mechanical hyperalgesia 
in CRPS (30). In a later study, this group showed reversal of cortical reorganization in S1 to 
be correlated with pain reduction in CRPS (31).
Cortical reorganization could thus explain some sensory features in CRPS. An example 






























on a more glove- or stocking-like distribution instead of being limited to the innervation 
territories of peripheral nerves (2, 31).
CRPS as a small-fibre neuropathy
CRPS has further been proposed to be a small-fibre neuropathy because of its similarity to 
generalized small-fibre-predominant polyneuropathies (34). Studies have found a decrease 
in epidermal nerve fibres and a decrease in sweat gland and vascular innervation in patients 
with CRPS (35). This could explain not only the (neuropathic) pain experienced in CRPS 
but also the trophic and vasomotor dysfunctions that are observed (34). The latter could be 
caused by antidromic release of neuropeptides, such as CGRP and SP, by these small fibres 
in response to trauma and inflammation (36). It is still not completely understood whether 
this small-fibre loss is a result of CRPS rather than a cause of this disease.
Psychological factors in CRPS
Physicians often consider CRPS patients to be psychologically different from other groups 
of patients. This is mostly due to the complexity and the poorly understood pathophysiology 
of this disease.
However, most  studies show no association between  the onset of CRPS and psycho-
logical factors such as depression, anxiety, paranoia and hostility/anger (37-39). There is 
some evidence for the influence of stressful life events before the onset of the disease (40). 
Although these factors may not play a role in the onset of CRPS, the probability still remains 
that these factors play a role in the maintenance of this disease (39, 41).
Taking the above into account, CRPS seems to be a multifactorial disease with a multi-
mechanism pathophysiology requiring a multimodal workup and treatment.
tReatmeNt
Effective treatment options in CRPS are limited and consist of non-invasive and invasive 
therapies.
Physical rehabilitation and physiotherapy have been shown to reduce pain and improve 
function in patients with CRPS. Physicians are therefore advised to start with active physical 
therapy in the treatment of CRPS (42).
Medication can be started in addition to physiotherapy. The choice of medication should 








In the Netherlands, free-radical scavengers (dimethyl sulphoxide or acetylcysteine) are 
advised for inflammatory symptoms (42). However, these drugs have not gained general 
international acceptance.
Immunomodulating medication reduces the manifestation of inflammation by influenc-
ing mediators of inflammation such as cytokines, neuropeptides, eicosanoids and amino ac-
ids. Standard use of immunomodulating medication in CRPS is still not common, although 
there is strong evidence for the use of bisphosphonates (43). For other immunomodulating 
medications, i.e. glucocorticoids, TNF-α antagonists, thalidomide and immunoglobulin, 
evidence is often conflicting and not sufficient to advise standard use (43).
analgetics/co-analgetics
Although there is insufficient evidence available on the treatment of nociceptive pain in 
CRPS, it seems wise to treat nociceptive pain according to the World Health Organization 
analgesic ladder, bar strong opioids (42).
The little evidence available on the treatment of neuropathic pain in CRPS supports the 
use of co-analgetics in the management of this disease (42, 44, 45). Gabapentin has been 
shown to lead to a reduction in pain symptoms in CRPS and can be used in the treatment 
of neuropathic pain (44).
If intractable pain persists, treatment with low-dose i.v. ketamine in long-standing CRPS 
can be considered. However, which dose and the length of treatment is still unclear (42). 
Liver function should be monitored frequently during treatment with i.v. ketamine. If liver 
enzymes increase, i.v. ketamine should be stopped immediately.
vasodilators
If vasomotor disturbance, leading to ‘cold’ CRPS, is the most prominent mechanism, a 
short-term treatment with a calcium channel blocker, an alpha-sympathetic blocker (46) or 
phosphodiesterase-5 inhibitor (47) can be considered. The medication should be stopped if 
no effect is achieved.
muscle relaxants/spasmolytics
With regard to the use of muscle relaxants in CRPS, research has mainly been focused on 
the intrathecal use of these drugs.
Intrathecal baclofen is likely to have a positive effect on dystonia in CRPS patients (48). 
However, given the side effects associated with intrathecal baclofen and the invasiveness of 































When there are indications for psychological problems, signs of chronic pain behavior, or 
inability to cope with the disease, referral to a multidisciplinary team including a psycholo-
gist should be considered.
Invasive treatments
Invasive treatments can be considered if the aforementioned therapies are insufficient, 
despite adequate treatment of the underlying pathophysiological mechanism.
‘Evidence-based Guidelines Development (EBGD) Guidelines on Complex Regional 
Pain Syndrome type I” (updated in 2014)  give a negative recommendation on the use of 
sympathetic blocks, such as stellate ganglion blocks, thoracic sympathetic nerve blocks and 
lumbar sympathetic nerve blocks, in the treatment of CRPS (42).
Spinal cord stimulation (SCS) may be considered if patients do not respond to phar-
macological treatments or rehabilitation therapies (4). The effect of this treatment on 
(neuropathic) pain and health-related quality of life in CRPS has been demonstrated in a 
randomized controlled trial (49). SCS is currently the only therapy with a multi-mechanism 
mechanism of action in CRPS. It has been shown to have a positive effect on both the 
somatosensory system and vasomotor disturbances (50).
PReveNtIoN
As treatment options for CRPS are limited, prevention of the disease would be the best 
medicine. Studies have shown supplementation with vitamin C (>500 mg day-1), initiated 
immediately after injury or surgery and continued for 45-50 days, helped to reduce the risk 
of developing CRPS (51-53).
PRoGNoSIS
The prognosis and outcome of CRPS is still difficult to predict. Resolution rates range 
between 74% in the 1st year to 36% after 6 years (5, 54).
The social impact of CRPS is significant (9, 54). Return-to-work rates vary, with one 
CRPS population study describing a permanent inability-to-work rate of 31% and a partial 








The current treatment of CRPS is based on the observed and reported signs and symptoms.
The present thinking is that these signs and symptoms reflect the underlying pathophysi-
ological mechanism leading to the different CRPS phenotypes (11). Consequently, it can be 
derived that patients with a warm, edematous extremity suffer from inflammation, while in 
patients with a cold, atrophic extremity the role of inflammation diminishes and vasomotor 
disturbance becomes the predominant process(8).
However, it has recently been shown that (a subgroup of ) cold CRPS patients can still 
suffer from inflammation (55). Therefore, the question arises whether the current diagnostic 
methods are sufficient. Perhaps the presence or absence of inflammation might be a better 
distinction for choosing the appropriate therapy.
It is now possible to determine if there is an ongoing inflammation in CRPS-affected 
extremities by determining the levels of pro-inflammatory cytokines in fluid from artificially 
induced skin blisters (13). However, this a time-consuming procedure that limits its use to 
the field of research and is therefore not easily available for use in daily clinical practice.
It is likely that multiple mechanisms simultaneously can play a role in the pathophysi-
ology of CRPS in an individual patient. As research continues to reveal more about the 
mechanisms involved in CRPS,  future treatment will presumably shift from a symptomatic 
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highlighting the Role of Biomarkers of 
Inflammation in the Diagnosis and management 














Complex Regional Pain Syndrome (CRPS) is characterized by continuous pain that is often 
accompanied by sensory, motor, vasomotor, sudomotor and trophic disturbances. If left 
untreated, it can have a significant impact on the quality of life of patients.
The diagnosis of CRPS is currently based on a set of relatively subjective clinical criteria: 
the New International Association for the Study of Pain clinical diagnostic criteria for CRPS. 
There are still no objective laboratory tests to diagnose CRPS and there is a great need for 
simple, objective and easily measurable biomarkers in the diagnosis and management of this 
disease.
In this review, we discuss the role of inflammation in the multi-mechanism pathophysi-
ology of CRPS and highlight the application of potential biomarkers of inflammation in the 
diagnosis and management of this disease.
Key PoINtS
Neurogenic inflammation, neuroinflammation and immune dysregulation contribute to 
inflammation in complex regional pain syndrome (CRPS).
Biomarkers reflecting these inflammatory mechanisms could aid in both the diagnosis and 
management of CRPS





























































Complex Regional Pain Syndrome (CRPS) is a painful disease of the extremities that is 
usually initiated by tissue damage, e.g., following fracture or surgery (1, 2). It is character-
ized by continuous pain that is disproportionate to the inciting event, and which can be 
accompanied by sensory, motor, vasomotor, sudomotor and trophic disturbances (3). The 
incidence of CRPS has been reported to vary between 5.5 and 26.2 per 100.000 person-
years and women are reported to be affected more often than men (1, 2).
Currently, the disease is diagnosed using a set of clinical criteria: the new International 
Association for the Study of Pain (IASP) clinical diagnostic criteria for CRPS (3). There is 
still no objective test available for diagnosis and/or management of this disease. Additional 
testing, such as blood tests and radiography, are only used to exclude other diseases, such as 
rheumatic diseases, in the differential diagnosis (4). Once CRPS is diagnosed, treatment is 
preferably conducted by a multidisciplinary team consisting of pain physicians, physiatrists, 
physiotherapists and psychologists. Because CRPS is considered to have a multi-mechanism 
pathophysiology, it is advised that the treatment be conducted in a mechanism-based 
manner: it should target the underlying pathophysiological mechanisms of disease in each 
unique CRPS case (5, 6).
If left untreated, CRPS can lead to a debilitating loss of function of the affected extremity 
and can have a significant social impact on the life of patients (7). It is therefore important 
that this disease is diagnosed early and treated with appropriate mechanism-based therapies. 
However, early diagnosis and therapy selection are often hampered due to the aforemen-
tioned lack of objective tests. Currently, physicians have to rely on  subjective symptoms 
reported by patients and relatively subjective signs observed during physical examination 
for diagnosis and management of CRPS. This subjectivity of symptoms and signs, which 
is often accompanied by a discrepancy between the symptoms and signs, leads to various 
diagnostic and therapeutic challenges for clinicians, such as delayed diagnosis and inap-
propriate selection of therapies. To make these matters more complicated, CRPS is a disease 
with a heterogeneous clinical presentation and there may be various disease subtypes with 
their own specific phenotype (8-10). These matters therefore not only complicate diagnosis 
of this disease but also the selection of therapies based on the underlying pathophysiologi-
cal mechanisms as, as at present, these underlying mechanisms are also deduced from the 
relatively subjective, and often discrepant, symptoms and signs.
 These diagnostic and therapeutic challenges highlight the need for simple, objective, and 
easily measurable biomarkers in the diagnosis and management of CRPS. In this review, we 
aim to highlight the application of potential biomarkers, specifically biomarkers of inflam-
mation, in the diagnosis and management of CRPS. For reasons of clarity, we have mostly 







PathoPhySIoLoGy of ComPLex ReGIoNaL PaIN 
SyNDRome (CRPS)
It has been generally accepted that multiple pathophysiological mechanisms contribute to 
CRPS. The following mechanisms have been implicated in the onset and maintenance of 
CRPS: inflammation, peripheral and central sensitization, altered sympathetic nervous sys-
tem function, changes in circulating catecholamine levels, endothelial dysfunction, cortical 
reorganization, and immune-acquired, genetic and psychological factors (11, 12). However, 
it is as yet unclear how and to what extent each of these mechanisms cause and maintain 
this disease.
In this article, we focus on the role of biomarkers of inflammation in the diagnosis and 
management of CPRS. We summarize the current knowledge on inflammation in CRPS 
as well as the related symptoms and signs. For further information on the role of other 
mechanisms in CRPS, we refer the reader to more extensive reviews (11, 13-15).
In CRPS, neurogenic inflammation, neuroinflammation and dysregulation of the im-
mune system have all been implicated as a source of inflammation. Peripheral neurogenic 
inflammation has long been implicated in the pathophysiology of CRPS (16). In peripheral 
neurogenic inflammation, primary afferent sensory neurons release neuropeptides that cause 
cutaneous  vasodilation (mainly through calcitonin gene-related peptide [CGRP]), changes 
in vascular permeability ( mainly through substance P [SP]),  increased protein extravasa-
tion, and increased leukocyte recruitment (17, 18). Weber et al. conducted a study using 
transcutaneous electrical stimulation via intradermal microdialysis capillaries and found 
significantly increased axon reflex vasodilation in the affected extremity of CRPS patients 
compared with healthy controls. This study further found increased protein extravasation in 
the affected extremity of these CRPS patients (19). These findings suggest an increased re-
lease of neuropeptides such as CGRP and SP by activated sensory neurons  in CRPS patients 
and thus point towards facilitated neurogenic inflammation in CRPS (19). This increased 
neuropeptide release may also account for symptoms such as allodynia, hyperalgesia, edema, 
vasodilation, and trophic abnormalities that are seen in CRPS patients (19, 20).
Besides neurogenic inflammation, recent studies have provided evidence supporting a 
role for neuroinflammation in CRPS (21, 22). Neuroinflammation refers to inflammation 
occurring within the nervous system (central nervous system and/or peripheral nervous 
system)  that is characterized by glial cell activation leading to an increased production of 
pro-inflammatory cytokines and chemokines (23). Neuroinflammation can be initiated by 
various forms of trauma and surgery, and it has also been suggested that it can be caused by 
increased neuronal activity of primary afferent nerve fibers and/or higher-order neurons (23, 
24). This latter phenomenon has been coined ‘neurogenic neuroinflammation’ and has also 
been implicated in CRPS (20, 24). Neuroinflammation can lead to various adverse effects, 



























































echronic pain  is established via central sensitization, which is induced and maintained by 
central cytokines, chemokines, and glia-produced mediators (23). Central sensitization is 
characterized by pain hypersensitivity and manifests clinically as dynamic tactile allodynia, 
secondary punctuate and/or pressure hyperalgesia, temporal summation and sensory after 
sensations (25). Symptoms of central sensitization have also been described in CRPS (25-
28) and have been attributed to a sensitization of the nociceptive system due to ongoing 
pain and, therefore, to continuous nociceptive input (11, 29). As neuroinflammation 
seems to drive central sensitization, and studies now suggest neuroinflammation may play 
a role in CRPS, it is possible that part of the symptoms of CRPS which are attributed to 
central sensitization can be caused not only by continuous nociceptive input, but also by 
neuroinflammation (21-23). Neuroinflammatory findings in CRPS are new and need to be 
studied in further detail, yet neuroinflammation represents an interesting therapeutic target 
in patients with symptoms and signs of central sensitization.
Although peripheral neurogenic inflammation has long been implicated in CRPS, it is 
only in recent years that evidence to support involvement of the immune system in CRPS 
has grown. Until recently, the involvement of the immune system in CRPS was a topic 
of intense debate: though classic signs of inflammation such as calor, dolor, rubor, tumor 
and functio laesa were often seen in CRPS patients, classic systemic markers of inflamma-
tion such as C-reactive protein and white blood cells were mostly within normal range in 
patients (30-32). Because of a lack of objective evidence for immune system involvement, 
a dysregulation of the immune system was disregarded for years as a possible pathophysi-
ological mechanism in CRPS. In recent years, however, due to a better understanding of 
the disease and improved research techniques, it has been possible to identify a role of the 
immune system in CRPS. Several lines of evidence now support a role for dysregulated 
immune activation and subsequent inflammation in CRPS: [1] increased levels of the pro-
inflammatory cytokines tumor necrosis factor (TNF)-α and interleukin (IL)-6 have been 
found in blister fluid of CRPS-affected extremities compared with clinically uninvolved 
contralateral extremities (33); [2] a higher prevalence of various autoantibodies has been 
identified in CRPS patients (34-37); and [3] indications of increased T lymphocyte activity 
have been found in CRPS patients (38).
These different sources of inflammation have provided us with a few promising biomark-
ers of inflammation in CRPS. Before we discuss these potential biomarkers of inflammation, 
however, we discuss the role of subtypes and phenotypical characterization in the diagnosis 







CRPS: SuBtyPeS aND PheNotyPeS
CRPS has been known a multitude of names in the past due to its varied presentation and 
ideas on its etiology. In 1993, a consensus meeting was held by the IASP Task Force on 
Taxonomy to develop a more general and neutral term for the symptoms and signs that 
make up this condition (39, 40). During this meeting, two types of CRPS were recognized: 
CRPS type I, previously known as reflex sympathetic dystrophy (RSD), in which there is 
no demonstrable nerve lesion; and CRPS type II, previously known as causalgia, in which 
there is demonstrable nerve lesion during physical examination and/or on electrodiagnostic 
testing (39-42). However, these subtypes do not differ in clinical symptoms and signs nor 
in their response to therapy (11). For the most part, the pathophysiological mechanisms 
also seem to be shared by both these subtypes (11). Therefore, in our practice, this subtype 
distinction is no longer used when diagnosing CRPS, and we will use the term CRPS to 
encompass both these subtypes throughout this article.
Bruehl et al. have conducted two cluster analysis studies in which they found that CRPS 
patients can be clustered into different subtypes based on symptoms and signs (8, 10). The 
first study was conducted in 2002; the authors performed a K-means cluster analysis on a 
group of 113 CRPS patients and were able to cluster patients into three distinct subgroups 
(8). Based on their findings, the authors proposed the following three subtypes: “1) a 
relatively limited syndrome with vasomotor signs predominating, 2) a relatively limited syn-
drome with neuropathic pain/sensory abnormalities predominating, and 3) a florid CRPS 
syndrome similar to descriptions of Classic RSD” as described by Gibbons and Wilson in 
1992 (8, 43). The second study was conducted in 2016; in this study, a two-step cluster 
analysis in a group of 152 CRPS patients provided evidence for a warm and cold CRPS 
subtype (10). The warm CRPS subtype associated with a more inflammatory phenotype 
with a warm, erythematous, swollen and sweaty extremity. By contrast, the phenotype of the 
affected extremity in the case of cold CRPS was characterized by a colder temperature, blue 
or pale skin, and also edema, although this latter characteristic was less common than in the 
warm cluster. The authors further showed that differences between these CRPS subtypes was 
based on multiple symptoms and signs that showed a consistent covariation across patients 
indicating the possibility of common underlying pathophysiological mechanisms which 
could be targeted by specific therapies (10). For example, the symptoms and signs (i.e., 
phenotype) typically associated with the warm CRPS subtype may reflect an underlying 
inflammatory mechanism that could be targeted with anti-inflammatory therapies.
The hypothesis that phenotypical characterization in CRPS can be used to assess the 
underlying pathophysiological mechanisms of disease, and consequently to select targeted 
therapies, was presented in an article by Birklein and Schlereth in 2015 (9). The authors de-
scribed two phenotypes of CRPS: the “peripheral inflammatory phenotype” reflecting clini-



























































ephenotype”  reflecting clinical symptoms and signs generated by the central nervous system 
(e.g. mechanical allodynia) (9). The problem with phenotypical characterization is, however, 
that clinicians are still dependent on relatively subjective symptoms and signs to characterize 
the subtype of CRPS that a patient may have. Another issue to take into consideration is 
the considerable amount of clinical overlap between the various phenotypes and subtypes, 
which could create confusion when determining underlying mechanisms of disease (10). 
In addition, phenotypical characterization can also misguide clinicians to a certain degree. 
For example, a clinician may disregard inflammation as an underlying pathophysiological 
mechanism in a patient with cold-type CRPS; however, we now know from a study in 
blister fluid that a subgroup of cold CRPS patients also suffers from inflammation (44). 
These issues highlight the need for simple, objective, and easily measurable biomarkers in 
the diagnosis and management of CRPS.
In the following sections we discuss potential biomarkers of inflammation in CRPS. 
We start by giving a general definition of a biomarker and the criteria that a biomarker for 
CRPS would need to meet. We then discuss potential biomarkers of inflammation that have 
been identified in CRPS and their possible role in the diagnosis and/or management of this 
disease. Lastly, we will provide suggestions for future research.
DefINItIoN of BIomaRKeR aND CRIteRIa foR 
CRPS
A biomarker is defined  as: “a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic responses 
to a therapeutic intervention” (45). Not only can a biomarker be used in regard to the 
response to a therapeutic intervention, it can also be used in the diagnosis, prognosis, and 
monitoring of diseases (45). In the case of CRPS, biomarkers could aid in various aspects 
of diagnosis and management: first, they could be used to aid the (early) diagnosis of this 
disease; second, they could be used, together with phenotypical characterization, to identify 
the underlying mechanisms of disease for selection of therapies; and third, they could be 
used to monitor disease activity and/or effects of therapy. We consider a biomarker that can 
be used in the first two situations as applicable in the diagnosis of CRPS, while a biomarker 
that can be used in the third situation is applicable in the management of this disease.
Most CRPS patients are treated by pain physicians in an outpatient clinic setting with 
limited access to extensive laboratory testing. Taking this into consideration, an ideal bio-
marker for CRPS would need to meet the following criteria: 1) the tissue or fluid that is 
required to determine the biomarker needs to be obtained in a simple manner in routine 
practice; 2) the measurement of the biomarker needs to be simple and reproducible using 







minimal risk to the patient, for example, a low-risk venipuncture versus a medium-risk skin 
biopsy.
In the following sections we will highlight a few potential biomarkers of inflammation 
in CRPS. In the future, these biomarkers could, for example, be used in patients with the 
“warm subtype” as described by Bruehl et al. or the “peripheral inflammatory subtype” as 
described by Birklein and Schlereth, to objectively identify inflammation and to start anti-
inflammatory therapies (9, 10).
For the purpose of simplicity, we have chosen to divide the biomarkers into two groups: 
‘potential biomarkers of neurogenic inflammation and neuroinflammation’ and  ‘potential 
biomarkers of immune dysregulation’ (Tables 1 and Table 2). We have further divided these 
biomarkers into local and systemic biomarkers: local biomarkers are markers that are typi-
cally measured in the affected tissues while systemic biomarkers are measured in blood. Both 
local and systemic biomarkers will be further subdivided into soluble and cellular markers 
where possible.
We acknowledge that there is a complex interplay between these inflammatory mecha-
nisms and that some, if not most, biomarkers can be applied to identify all mechanisms.























CGRP Soluble Venous blood Neurogenic + ?
SP Soluble Venous blood Neurogenic ? ?
CGRP calcitonin gene-related peptide, CRPS complex regional pain syndrome, PET positron emission 
tomography, SP substance P, + indicates a possible role as a biomarker in the diagnosis and/or manage-
ment of CRPS, ? indicates that insufficient information is currently available to determine a possible 
role as a biomarker in the diagnosis and/or management of CRPS.
aThe biomarker aids the (early) diagnosis of this disease and/or it could be used, together with pheno-
typical characterization, to identify the underlying mechanisms of disease for selection of therapies.




























































PoteNtIaL BIomaRKeRS of NeuRoGeNIC 
INfLammatIoN aND NeuRoINfLammatIoN
Local biomarkers: Although this article mainly discusses biochemical markers of inflammation 
that can be measured in clinical laboratories, we would like to highlight the findings by Jeon 
et al. and Jung et al. regarding neuroinflammation (21, 22). Jeon et al. conducted a study 
in which they used [11C]-(R)-PK11195 positron emission tomography (PET) to observe 
microglial activation in CRPS patients and to identify whether there was an association with 
symptom severity (21). The authors found a significantly higher distribution volume ratio 
(DVR) of [11C]-(R)-PK11195 in the caudate nucleus, putamen, nucleus accumbens and 
thalamus of CRPS patients than in the healthy controls. They further found a statistically 
significant, positive correlation between [11C]-(R)-PK11195 DVR and pain severity (21). 










tNf-α Soluble Blister fluid + +
IL-6 Soluble Blister fluid + +
tryptase Soluble Blister fluid + +
mast cell numbers Cellular Skin biopsies + +
Systemic markers
CD14+CD16+ monocytes Cellular Venous blood ? ?
CD8+ t lymphocytes Cellular Venous blood ? ?
sIL-2R Soluble Venous blood + ?
autoantibodiesc Soluble Venous blood ? ?
miRNa Soluble Venous blood + +
CRPS complex regional pain syndrome, IL-6 interleukin-6, miRNA microRNA, sIL-2R soluble in-
terleukin-2 receptor, TNF-α tumor necrosis factor-α, + indicates a possible role as a biomarker in the 
diagnosis and/or management of CRPS, ? indicates that insufficient information is currently available 
to determine a possible role as a biomarker in the diagnosis and/or management of CRPS
aThe biomarker aids the (early) diagnosis of this disease and/or it could be used, together with pheno-
typical characterization, to identify the underlying mechanisms of disease for selection of therapies.
bThe biomarker could be used to monitor disease activity and/or effects of therapy.
cAutoantibodies studied in CRPS: autoantibodies against autonomic nervous system structures(34), 
autoantibodies against autonomic nervous system autoantigens (e.g. β2-adrenergic receptor and/or 







These findings point towards microglial activation and neuroinflammation in CRPS with a 
possible association between degree of neuroinflammation and pain severity.
Jung et al. conducted an explorative study in which they studied the correlation between 
peripheral metabolites in blood and urine, central neurometabolites using proton magnetic 
resonance spectroscopy (1H-MRS) and neuroinflammation using [11C]-(R)-PK11195 PET. 
The authors found statistically significant positive correlations between the levels of lipid 
13a and lipid 09 relative to total creatine and neuroinflammation in certain brain regions 
(22). They further found that peripheral pH, glucose, CO2, basophil and creatinine levels 
were associated with an increase or decrease of the level of neuroinflammation in the brain 
of CRPS patients (22). The authors suggest that characterization of peripheral and central 
metabolites may help to understand the role of neuroinflammation in the pathophysiology 
of CRPS. They further suggest that central lipid levels may be used as a biomarker for 
neuroinflammation.
The results from these two studies pave the way for a new field of research on the role 
of neuroinflammation in the pathophysiology of CRPS. These results, however, need to 
be further analyzed in a clinical context and we cannot yet determine the role of these 
techniques and markers in the diagnosis and management of CRPS.
Systemic biomarkers: four studies measured venous blood levels of the soluble neuro-
peptide CGRP  in CRPS patients (32, 46-48). Blair et al. conducted a study in which they 
measured CGRP levels in the blood of CRPS patients and healthy controls: blood CGRP 
levels were higher in the patients than in the controls (46). Birklein et al. conducted a study 
in which they measured serum CGRP levels in CRPS patients and age- and gender-matched 
healthy controls. The authors had some interesting findings: first, serum CGRP levels were 
significantly higher in CRPS patients than in controls; second, serum CGRP levels did not 
differ between the affected and contralateral limb; third, serum CGRP normalized in the 
group of patients who agreed to a follow-up visit at 9 months after the initial assessment, this 
normalization was accompanied by a clinical improvement of local inflammatory symptoms, 
but not a reduction in pain; and fourth, higher serum CGRP levels correlated significantly 
with the incidence of nerve lesions and hyperhidrosis, but not with pain, CRPS duration, or 
other clinical symptoms (47). Schinkel et al. conducted two studies in which they assessed 
blood CGRP levels in CRPS patients. In the first study, no difference was found in blood 
CGRP levels between patients with mostly acute CRPS and healthy age and gender matched 
controls (32). In the second study, they found significantly lower levels of CGRP in the blood 
of patients with chronic CRPS than healthy controls, although the authors state that these 
differences were marginal (48). Though the results from these studies contradict each other, 
there may possibly be a role for serum CGRP in the diagnosis of an underlying neurogenic 
mechanism in CRPS, especially in patients with sudomotor (sweating) symptoms. Based 
on these findings, we cannot conclude whether this marker can be used in the management 



























































eCGRP antagonists have, to our knowledge, not yet been tested in CRPS patients. However, 
it is not unthinkable that serum CGRP levels could be used in the future to select CRPS 
patients who would benefit from this therapy, if these therapies are ever proven effective in 
this disease.
The two studies by Schinkel et al. also examined  SP levels in the venous blood of CRPS 
patients (32, 48). In the first study, the authors found significantly higher SP levels in the 
blood of patients with mostly acute CRPS than in the blood of healthy controls (32). In the 
second study, the authors found higher blood SP levels in CRPS patients than in healthy 
controls, although this difference was not statistically significant. There was, however, a 
significant difference between acute and chronic CRPS with acute CRPS patients having 
significantly lower levels of SP than chronic CRPS patients (48). By contrast, the study 
by Blair et al. showed no difference in blood SP levels between CRPS patients and healthy 
controls (46). To our knowledge, these studies did not look at the correlation between SP 
and clinical symptoms (32, 46, 48). Based on the findings from these studies, we cannot 
determine the place of SP in the diagnosis and/or management of CRPS, however, we can 
conclude that there may be a role for SP in the pathophysiology of CRPS.
PoteNtIaL BIomaRKeRS of ImmuNe 
DySReGuLatIoN IN CRPS
Local biomarkers: One of the first studies that proved inflammation plays a significant role 
in CRPS also gave us some of the first soluble local inflammatory biomarkers for this disease 
(33). In 2002, Huygen et al. conducted a study in which they assessed whether changes in 
levels of inflammatory mediators could be found in limbs of CRPS patients. The authors 
induced artificial skin blisters in the CRPS-affected and contralateral limb and subsequently 
extracted the fluid from these blisters. They found significantly elevated levels of the pro-
inflammatory cytokines TNF-α and IL-6 in the affected limbs (33). Based on these findings, 
their group decided to treat two patients with the TNF-α inhibitor infliximab. This treat-
ment resulted in considerable clinical improvement in both patients and was associated with 
a substantial decline of TNF-α and IL-6 levels in blister fluid (49). These results illustrate 
that blister-fluid TNF-α and IL-6 levels can be considered as local biomarkers with two 
potential applications: firstly, for determining the inflammatory component in CRPS and 
thus determining the eligibility of a patient for treatment with a TNF-α inhibitor such 
as infliximab, and secondly, for monitoring treatment response to this TNF-α inhibitor. 
However, it should be noted that randomized controlled trials are still required to assess the 
therapeutic effects of TNF-α inhibitors in CRPS (50).
Another potential local biomarker of inflammation in CRPS is the mast cell and its 







tryptase (51, 52). Significantly higher levels of tryptase have been found in blister fluid of 
the affected limb of CRPS patients than in the contralateral limb (53). In addition, blister 
fluid tryptase levels were found to have a significant positive correlation with patient pain 
scores (53). In further support of a role for mast cells in CRPS are the findings by Birklein 
et al. describing higher mast cell numbers in skin biopsies of the affected limb than in skin 
biopsies of the contralateral limb (54). Interestingly, mast cell numbers seem to be increased 
only in the early stages of CRPS and not in long-standing disease (54, 55). Consequently, 
determining local mast cells could represent a diagnostic biomarker of inflammation associ-
ated with early-stage CRPS. If elevated mast cell numbers or specific mast cell products are 
found, mast cell-directed therapy could be considered (56, 57) and determining local mast 
cell accumulation or their products (e.g. tryptase) could be used to monitor treatment effect.
Systemic biomarkers:  Circulating monocytes can be subdivided into three phenotypically 
distinct subpopulations based on the expression of CD14 and CD16, i.e., CD14+CD16- 
monocytes, CD14+CD16+ monocytes and CD14+/-CD16++ monocytes (58, 59). The mono-
cyte subset composition is altered in peripheral blood in the case of inflammatory diseases, 
with mostly an increased fraction of the pro-inflammatory CD14+CD16+ monocytes (also 
designated as intermediate monocytes) (59, 60). Moreover, in sarcoidosis, for instance, the 
relative abundance of circulating CD14+CD16+ monocytes has been found to correlate 
positively with serum angiotensin-converting enzyme (ACE) levels of patients, suggesting 
that it represents a marker for disease activity (61).  In CRPS patients, an elevated fraction 
of pro-inflammatory CD14+CD16+ monocytes in venous blood has also been observed in 
comparison with healthy controls (62). CD14+CD16+ monocytes are poor producers of the 
anti-inflammatory cytokine IL-10 as compared to the classical CD14+CD16- monocytes, 
whereas both monocyte subpopulations produce similar amounts of pro-inflammatory 
cytokines (62, 63). These findings suggest that the increase in CD14+CD16+ monocytes 
in CRPS may contribute to and reflect a pro-inflammatory status (62). Moreover, the 
study by Ritz et al. observed a positive correlation between the relative abundance of  the 
CD14+CD16+ monocyte subset and the clinical sign of cold allodynia which can indicate a 
role of these monocytes in the development of central sensitization in CRPS patients (62). 
When interpreted with caution, there might be a diagnostic role for monocyte subset de-
termination in the assessment of the inflammatory status and central sensitization in CRPS 
patients. However, further research into this topic is clearly needed as it is not clear whether 
these pro-inflammatory monocytes have a pathogenic quality or are merely a result of an 
already ongoing inflammatory process in CRPS. Additionally, monocytes that infiltrate tis-
sues differentiate further into macrophages of which different subtypes exist; future  research 
on the relative tissue distribution of these pro-inflammatory M1 and anti-inflammatory M2 
macrophages in CRPS could thus also be of interest (64, 65).
Circulating T lymphocyte subsets represent another example of potential cellular bio-



























































ein venous blood of CRPS patients (31, 62, 66). These studies, however, show conflicting 
results when it comes to alterations in circulating T lymphocyte subsets. For example, while 
Kaufmann et al. found significantly lower absolute numbers of cytotoxic CD8+ T lympho-
cytes in CRPS patients than in healthy controls, Ribbers et al. observed no difference in the 
absolute numbers of this subset, and Ritz et al. found no difference in the percentage of this 
subset between CRPS patients and healthy controls (31, 62, 66). Interestingly, Kaufmann 
et al. did not find any correlation between CD8+ T lymphocytes and pain, as measured on 
a Visual Analog Scale ranging from 0-10 in CRPS patients(66). Based on these conflicting 
results, we cannot draw a conclusion on whether T lymphocyte subset measurement in 
peripheral blood can currently be used as a biomarker for diagnosis and/or management of 
CRPS. Yet the existence of many different T lymphocyte subsets, including different types 
of T helper subsets, clearly warrants further study into the relation between T lymphocytes 
and CRPS(67, 68).
Not only can T lymphocyte involvement be assessed at a cellular level, but it can also 
be assessed using a soluble marker for T lymphocyte activity(69). The soluble interleukin-2 
receptor (sIL-2R), also termed CD25, is a truncated protein that is released from activated 
T cells: hence, it is a surrogate marker for T cell activation (69, 70). Peripheral blood levels 
of the sIL-2R thus reflect the level of T cell activation in an individual and elevated blood 
levels of sIL-2R correlate with disease activity in for instance rheumatoid arthritis, systemic 
lupus erythematosus, and sarcoidosis, diseases in which enhanced T cell activity is centrally 
involved (71-75). Our group measured sIL-2R serum levels in CRPS patients and compared 
this to the serum sIL-2R levels of healthy controls (38). We found significantly higher levels 
of the sIL-2R in CRPS patients than in healthy controls (38). Serum sIL-2R further seems to 
be a good discriminator between patients with CRPS and healthy controls, showing a high 
sensitivity (90%) and specificity (89.5%) (38). These results seem promising: firstly, they 
may be indicative of a role for pathogenic T lymphocyte activation in CRPS, and secondly, 
they could lead to the use of the sIL-2R as a biomarker in the diagnosis and/or management 
of CRPS. However, the place of this marker in the diagnosis and/or management of this 
disease is yet to be determined and we are currently validating these findings in further 
studies.
Autoantibodies represent another example of soluble biomarkers. Autoantibodies are 
commonly used as biomarkers for diagnosis and monitoring of inflammatory diseases and 
autoimmune diseases (76).  Multiple studies have described various autoantibodies in CRPS 
(34-37). One study identified autoantibodies against autonomic nervous system structures 
in a small subset of CRPS patients: five out of twelve CRPS patients were positive for these 
autoantibodies (34). Another study found that ~30-40% of their CRPS patient group had 
autoantibodies against an autonomic nervous system autoantigen(35). In a follow-up study, 
this group aimed to identify the antigens targeted by these autoantibodies and found agonis-







subset of their CRPS patients (36). A third study found a higher prevalence of anti-nuclear 
antibody (ANA) positivity in CRPS patients than in healthy controls (33% vs 4%, P<0.001) 
(37). Although these data support involvement of an autoimmune component in CRPS, it 
is still unclear whether these autoantibodies are pathogenic or whether they are a result of 
this disease. Consequently, their role as biomarkers in the diagnosis and/or management 
of CRPS needs further evaluation, especially in comparison with other diseases that are 
included in the initial differential diagnosis.
Finally, we would like to highlight the potential role of systemic micro-ribonucleic acids 
(miRNAs) in the diagnosis and management of CRPS (77). miRNAs are small non-coding 
RNA molecules that suppress protein synthesis through messenger RNA (mRNA) silencing 
(78, 79). Orlova et al. have suggested the potential application of blood miRNA profiling in 
the selection of treatments for CRPS patients and in the stratification of CRPS patients in, 
for example, clinical trials (80). They compared blood miRNA profiles of CRPS patients with 
those of healthy controls and found a significant differential expression of 18 miRNAs in the 
CRPS group (80). They were further able to stratify the study population into three clusters, 
with one cluster containing 60% of the CRPS patients and no healthy controls. Further 
analysis of this CRPS-only cluster revealed significant alterations in additional miRNAs 
and inflammatory markers compared to the rest of the CRPS patients and healthy controls 
(80). Though the clinical relevance is still not clear, these findings suggest that differentially 
expressed miRNAs could help to identify different CRPS subtypes and could further lead to 
the identification of additional  inflammatory markers that are specific to these subtypes (77, 
80). In addition, miRNA profiling could also be used as a prognostic biomarker to identify 
responders to specific therapies (81). Thus, the application of miRNA profiling could be 
useful in the diagnosis as well as the management of CRPS; however, research on this subject 
is still in its initial phase and more research is needed to validate current results.
BIomaRKeRS IN CRPS: LImItatIoNS, 
CoNSIDeRatIoNS aND ReCommeNDatIoNS foR 
futuRe ReSeaRCh
Although the findings mentioned above are promising, there are still no biomarkers that 
have been implemented in the routine clinical practice surrounding CRPS patients. It is 
clear that we still have a long path ahead when it comes to the identification, validation and 
application of biomarkers in the diagnosis and management of CRPS. As this disease is cur-
rently diagnosed using a set of relatively subjective clinical criteria, an objective biomarker 
would be welcomed with open arms by pain physicians. There are, however, matters to be 




























































First, acquisition of the marker is of great importance: is it acquired locally or systemi-
cally? Some of the markers mentioned above are acquired in blister fluid and/or skin biopsies 
while others are measured in venous blood. The techniques for skin blisters and skin biopsies 
are considered to be of a higher risk to the patient and more invasive than a venipunc-
ture and require a close follow-up to assess healing of the damaged skin. The skin blister 
technique is also time consuming and requires pain physicians to have access to materials 
and devices not usually available in routine practice (33). Second, is it simple to obtain in 
routine practice? In general, a marker that can be measured in venous blood is easier to 
obtain in routine practice than a marker that needs to be measured in skin biopsies or blister 
fluid. Furthermore, certain techniques require a certain amount of training. Pain physicians 
would thus need to be trained in obtaining skin biopsies and inducing artificial skin blisters. 
Third, is the biomarker easy to measure? This question is largely dependent on whether an 
affiliated laboratory has the facilities to determine the aforementioned markers; for example, 
an enzyme-linked immunosorbent assay (ELISA) is a relatively simple technique to quantify 
substances such as autoantibodies, while a cell-based assay is a more complex technique 
which is often not routinely available. Lastly, and most importantly, is it at a minimal risk 
to the patient? Patients with CRPS have continuing pain of the affected limb that can be 
worsened by touch or any form of contact (allodynia and/or hyperalgesia). Performing a 
skin biopsy or inducing a skin blister in the affected limb can temporarily increase the pain 
a patient is experiencing. In contrast, venipuncture is usually conducted in the contralateral 
table 3 An overview of the discussed biochemical biomarkers of inflammation in complex regional 
pain syndrome together with an overview of considerations for routine practice.






CGRP Venous blood + + +
SP Venous blood + + +
tNf-α Blister fluid - + -
IL-6 Blister fluid - + -
tryptase Blister fluid - + -
mast cell numbers Skin biopsies - - -
CD14+CD16+ monocytes Venous blood + + +
CD8+ t lymphocytes Venous blood + + +
sIL-2R Venous blood + + +
autoantibodies Venous blood + +/- +
miRNa Venous blood + - +
CGRP calcitonin gene-related peptide, IL-6 interleukin-6, miRNA microRNA, sIL-2R soluble inter-







limb, or in the case of the lower limb, it is conducted in an arm, thereby avoiding the painful 
limb.
We are aware that biomarkers of inflammation can also be detected in other tissues 
and fluids, for instance in cerebrospinal fluid (CSF) (82-84). However, we chose not to 
include findings in CSF as the technique to acquire this fluid, a lumbar puncture, is quite 
invasive and is currently only used in a research setting in CRPS. Furthermore, we chose 
to cover (mostly) biochemical and cellular markers of inflammation in CRPS, however, 
biomarkers are not only limited to biochemical or cellular findings but also can be clinical 
or radiographic in nature. In the future, it would be interesting to review all these different 
forms of biomarkers in CRPS.
In addition to the biomarkers discussed  in this article, future research on the identifica-
tion of other potential biomarkers of inflammation in CRPS is indicated. A molecule of 
interest is, for instance, the high mobility group box 1 (HMGB1) protein, a ligand for 
multiple immune receptors, that has been implicated in neuropathic pain and in various 
inflammatory diseases (85, 86). To our knowledge, HMGB1 has not yet been measured in 
CRPS patients. Furthermore, genetic and epigenetic analysis may represent an interesting 
future field of research, not only for identification of biomarkers but also to enhance our 
pathogenetic understanding of CRPS.
Future research should also focus on other non-invasive options for detection of bio-
markers in CRPS, for instance salivary analysis (87). To our knowledge, only one study has 
used salivary analysis to analyze whether free radicals and oxidative stress are involved in 
the pathophysiology of CRPS (88). Although further optimization and validation of this 
approach for detection of  most inflammatory markers is required (87), it may represent 
a  promising method for non-invasive monitoring of inflammatory markers that warrants 
further exploration in CRPS.
While writing this article, we noticed that most biomarkers of inflammation that we 
have described have not yet been correlated to clinical symptoms and signs and thus a 
specific subtype or phenotype of CRPS. Future research should thus focus on identifying 
correlations between potential biomarkers of inflammation and clinical symptoms and signs 
of CRPS. Furthermore, validation studies are needed before any of the described markers 
can be implemented as routine biomarkers in the diagnosis and management of CRPS. 
In addition, considering the multi-mechanism pathophysiology of CRPS, it would be 
interesting for future studies to investigate biomarkers that that could identify the other 





























































The importance of identification and validation of biomarkers in CRPS lies in the objective 
quality they bring to both the diagnosis and management of this disease. In the case of 
biomarkers of inflammation in CRPS, they can potentially be used to: 1) diagnose patients 
with CRPS; 2) aid phenotypical characterization in identifying underlying inflammatory 
mechanisms; 3) stratify patients according to who would or would not benefit from anti-
inflammatory therapies; and 4) monitor the effects of these therapies.
Although there are a number of promising biomarkers of inflammation described in 
CRPS, it is still difficult to determine the place of these markers in the diagnosis and man-
agement of CRPS based on the current literature. Future studies should focus on finding 
correlations between clinical symptoms and signs and these biomarkers.
As CRPS is a multi-mechanism disease, we currently do not believe that there will be 
one biomarker specific to this disease. We believe that in the future, multiple biomarkers 
will be used together with phenotypical characterization to identify which mechanisms are 
prominent in each CRPS case. The results will then be used to guide physicians in the 
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The immune system has long been thought to be involved in the pathophysiology of Com-
plex Regional Pain Syndrome (CRPS). However, not much is known about the role of the 
immune system and specifically T-cells in the onset and maintenance of this disease.
In this study we aimed to evaluate T-cell activity in CRPS by comparing blood soluble 
interleukin-2 receptor (sIL-2R) levels between CRPS patients and healthy controls.
CRPS patients had statistically significant elevated levels of sIL-2R as compared to 
healthy controls (median sIL-2R levels 4151 pg/ml (Q3-Q1 =  5731pg/ml – 3546 pg/ml) 
versus 1907 pg/ml (Q3-Q1:  2206 pg/ml – 1374 pg/ml),  p<0.001, respectively). Further-
more, sIL-2R level seems to be a good discriminator between CRPS patients and healthy 
controls with a high sensitivity (90%) and specificity (89.5%).
Our finding indicates increased T-cell activity in patients with CRPS. This finding is of 
considerable relevance as it could point towards a T-cell mediated inflammatory process in 
this disease. This could pave the way for new anti-inflammatory therapies in the treatment 
of CRPS. Furthermore, sIL-2R could be a promising new marker for determining inflam-





















































Complex regional pain syndrome (CRPS) is a clinical disorder characterized by severe pain 
in an affected extremity that is accompanied by sensory, motor, vasomotor and sudomotor 
disturbances (1). CRPS is often preceded by an injury to an extremity such as a fracture or 
surgery (2).
The exact pathophysiology of CRPS is still unknown. CRPS is considered to be a 
multi-mechanism disease (3). The following mechanisms have been proposed to play a role 
in CRPS: inflammation; central and peripheral sensitization; altered sympathetic nervous 
system function; endothelial dysfunction; brain plasticity and psychological factors (3-5).
Inflammation as an underlying pathogenic mechanism for CRPS has long been a 
topic of debate, as systemic markers of inflammation such as erythrocyte sedimentation 
rate (ESR), c-reactive protein (CRP) and white blood cell count (WBC) are usually not 
elevated in CRPS patients (6-8). However, classic signs of inflammation such as pain, swell-
ing and redness are often present during physical examination, especially in the initial stages 
of the disease, suggesting that inflammation does contribute to CRPS (9, 10). The latter is 
supported by research findings that demonstrated increased levels of the pro-inflammatory 
cytokines tumor necrosis factor alpha (TNF-α) and interleukin (IL)-6 in skin blister fluid 
of the affected limbs versus the unaffected limbs  of CRPS patients (11, 12). Further, recent 
studies have confirmed evidence of systemic inflammation in venous blood of CRPS patients 
(7, 13).
An interesting theory on inflammation in CRPS was put forward by Goebel et al. sug-
gesting that CRPS is a novel kind of antibody mediated autoimmune disease (14).
To expand on this theory, our research group previously analyzed the presence of anti-
nuclear antibodies (ANA) and anti-neuronal antibodies in CRPS patients and demonstrated 
increased ANA positivity in CRPS patients as compared to healthy controls (33% vs 4% 
respectively, p<0.001) (15). The frequency of positivity for anti-neuronal antibodies did not 
differ between the groups (15).  Considering our findings and those of Goebel et al.  we 
could not define CRPS as an antibody mediated autoimmune disease in accordance with 
Witebsky’s criteria for autoimmune diseases (14-19).  Therefore, we shifted our focus to 
exploring the role of T-cells in the inflammation seen in CRPS.
Hitherto, very few studies have been conducted on the role of T-cells in CRPS (6, 20, 
21). These studies were conducted using different methodologies and had different outcome 
parameters, making comparison between the studies and thus establishment of a firm con-
clusion difficult. Furthermore, some data presented in these studies are contradictory, e.g. 
while one study showed no difference in blood lymphocyte populations (i.e. (cytotoxic) 
CD8+ T-cells, CD4+ T-cells, B-cells and natural killer (NK)-cells) between CRPS patients 
and healthy controls, another study found that CRPS was associated with a significant 







Another approach to study T-cell involvement in CRPS is to analyze whether there are 
indications of increased T-cell activity in CRPS, for instance by measurement of soluble 
interleukin-2 receptor levels in peripheral blood.
Interleukin-2 (IL-2) is a cytokine crucially important in regulating activation, prolifera-
tion and survival of different T-cell subsets (22, 23). This effect of IL-2 is mediated through 
the IL-2 receptor which consists of the common g-chain (CD132), a β-chain (CD122) and 
an α-chain (CD25) (22, 24). CD25 is strongly expressed on activated T-cells which also 
secrete this molecule as a soluble variant (referred to as soluble IL-2 receptor; sIL-2R) from 
the cell membrane into the circulation (22, 25, 26).
Peripheral blood levels of sIL-2R have been found to reflect the level of T cell activation 
and elevated sIL-2R levels correlate with disease activity in for instance rheumatoid arthritis 
and sarcoidosis, diseases in which T-cell activation is centrally involved (22, 24, 25, 27-30).
Finding increased levels of sIL-2R in CRPS could be indicative of a T-cell mediated 
inflammatory process in this disease. This finding could contribute to a better understand-
ing of the underlying inflammatory pathophysiological mechanism in CRPS. This could 
further lead to the development and application of (new) therapies in the treatment of CRPS 
patients with (T-cell mediated) inflammation as an underlying mechanism of their disease.
Therefore, the aim of this study was to evaluate T-cell activity in CRPS by examining 
the levels of sIL-2R in a group of CRPS patients and comparing these to sIL-2R levels in a 
group of healthy controls.
mateRIaLS aND methoDS
ethical approval
This study was approved by the Medical Ethics Committee of Erasmus MC University 
Medical Center Rotterdam (MEC-2016-172).
Patients and controls
Patients who visited the Center for Pain Medicine at Erasmus MC University Medical Cen-
ter Rotterdam between 2001 and 2007 and fulfilled the Harden-Bruehl diagnostic criteria 
for CRPS  were invited to participate in various ongoing studies (31).
In the context of these studies, venous blood samples were drawn from patients and 
plasma was stored in a refrigerator at -80 degrees Celsius for use in future research with 
permission of the patients.
For this study we examined the levels of sIL-2R in the plasma of 80 adult patients with 
CRPS type I and compared this to sIL-2R levels measured in 76 anonymous healthy blood 





















































Venous blood samples were centrifuged at 3000 rpm immediately after collection for a 
duration of 10 minutes. Plasma was stored at -80 degrees Celsius and thawed to room 
temperature for sIL-2R analysis.
sIL-2R plasma levels were quantified using an enzyme linked immunosorbent assay 
(Human sCD25/sIL-2R ELISA KIT, Besancon, Cedex, France) in accordance with the 
manufacturer’s  instructions. sIL-2R levels are expressed in picograms per milliliter (pg/ml), 
and levels >2500 pg/ml are considered elevated.
Statistical analysis
Descriptive statistics were used to determine the frequencies of the demographic variables 
and plasma sIL-2R levels and to describe measures of central tendency and of variability. The 
Shapiro-Wilk test was used to test the distribution of these variables for normality. Results 
are reported in medians and interquartile ranges (Q3-Q1) if the distribution is skewed and 
otherwise in means and standard deviations (sd).
Differences in sIL-2R levels between the CRPS patients and the healthy blood bank 
donors were analyzed  using the Independent-Samples Mann-Whitney U test (two-sided).
A possible association between sIL-2R levels of the CRPS patients, their age, gender and 
duration of the CRPS was also explored. An association with gender was evaluated using the 
Independent-Samples Mann-Whitney U test (two-sided). With regard to the age of patients 
and the duration of CRPS the Spearman’s rank correlation was used (two-sided).
A binary logistic regression was used to evaluate the contribution of the level of sIL-2R 
to the prediction of the group (CRPS patients vs healthy controls). A Receiver Operating 
Characteristic (ROC) curve was computed. The sensitivity, specificity, positive (PPV) and 
negative predictive value (NPV) of sIL-2R were calculated.
The alpha level for statistical significance was set at 0.05. Analyses were performed using 
IBM SPSS Statistics 21.
ReSuLtS
Plasma was available from 80 CRPS patients. The characteristics of our CRPS patient group 
are depicted in Table 1.
The median sIL-2R level of the CRPS group was statistically significant higher compared 
to the median sIL-2R level of the control group. The median of the CRPS patients was 4151 
pg/ml (Q3-Q1 =  5731 pg/ml – 3546 pg/ml) and that of the control subjects 1907 pg/ml 
(Q3-Q1:  2206 pg/ml – 1374 pg/ml),  p<0.001 (see Figure 1).
Plasma levels of sIL-2R between male and female CRPS patients were also compared. 







5602 pg/ml, Q3-Q1= 5829 pg/ml – 3921 pg/ml vs women 4016 pg/ml, Q3-Q1 = 4951 pg/
ml - 3286 pg/ml, p=0.03) (see Figure 2).
No association was found in the CRPS patient group between sIL-2R levels and the 
duration of disease (rs=-0.18, p=0.10), nor between sIL-2R levels and the age of patients 
(rs=0.12, p=0.28).
The level of sIL-2R showed a favorable discrimination between CRPS patients and 
healthy controls. The sensitivity was observed to be 90%, specificity 89.5%, PPV 90% and 
NPV 89.5%, using a cut value of 0.5, which corresponds with an sIL-2R level of 3730 pg/
ml (see Table 2, Figure 3).
table 1 Characteristics of the CRPS patients.
Characteristics n=80
Women (n, %) 67 (83.8)
Age in years (mean, sd) 44.4 (12.25)
CRPS duration in months (median, Q3-Q1) 11 (36-5)
Upper limb (n, %) 46 (57.5)
Warm/cold/unknown CRPS
Warm CRPS (n, %) 30 (37.5)
Cold CRPS (n, %) 44 (55.0)
Unknown (n, %) 6 (7.5)
Precipitating injury
Trauma (n, %) 51 (63.8)
Surgery (n, %) 21 (26.3)
Spontaneous onset (n, %) 6 (7.5)





































































table 2 Results of the binary logistic regression analysis.
95% CI for Odds Ratio
B (SE) [p-value] Lower Odds Ratio Upper
Included
Constant -6.96 (1.11) [<0.001]
sIL-2R 0.002 (< 0.001) [<0.001] 1.002 1.002 1.003




figure 3 Receiver Operating Characteristic curve of sIL-2R as a predictor of group (CRPS patients vs 
healthy controls). Area under the curve 0.958 (se 0.016), p<0.001.
DISCuSSIoN
This study was conducted to explore whether T-cell activation is involved in the patho-
physiology of CRPS. To this end, venous blood levels of sIL-2R in CRPS patients were 
compared to those of healthy controls. Our data clearly demonstrate that plasma sIL-2R 
levels are significantly elevated in CRPS patients. This finding is of considerable relevance as 
it indicates increased T-cell activity in CRPS and therefore could point towards an underly-




















































There is one earlier study which has shown significantly elevated plasma levels of sIL-2R 
in CRPS patients (32). However, the aim of this study was to conduct an explorative analysis 
of various plasma analytes in CRPS patients and to subsequently derive different CRPS 
clusters based on their findings (32). The authors did not relate this finding of higher plasma 
levels of sIL-2R to T cell activity (32). This seems to be more an ancillary finding, but it 
strongly supports our results.
In our study we observed higher sIL-2R plasma levels in men with CRPS as compared 
to those in women with CRPS.  We could not compare the gender distribution of sIL-2R 
levels in our CRPS group to the group of healthy controls as this was an anonymous group 
without any available demographic data. However other studies do not report elevated blood 
sIL-2R levels in healthy men compared to healthy women (22, 33-35).
Our finding of a significant difference in sIL-2R levels between CRPS men and women 
conflicts with the finding of the previously mentioned explorative study (32) . This study 
found no differences in sIL-2R levels between men and women with CRPS (32). One 
explanation for the contradictory results could be the possibility of higher disease severity in 
our group of male CRPS patients, as sIL-2R levels have been shown to correlate with disease 
severity in other disease entities (28).
We found no association between sIL-2R levels and age in the CRPS group. Studies 
in healthy individuals have shown sIL-2R levels to vary with age (22). Children (age 1-14 
years) and the elderly (age 67-99 years) have been shown to have higher sIL-2R levels as 
compared to (young) adults (age 22-67)  (22, 33, 35). This could explain why no association 
was found between sIL-2R levels and age as our CRPS patient sample consisted mainly of 
(young) adults with a mean age of 44.4 years (sd 12.25).
No association was found between sIL-2R levels and duration of disease, suggesting 
immune system activation throughout the entire disease course in a (subgroup) of CRPS 
patients.
Finally, our findings show sIL-2R level to be a good discriminator between CRPS 
patients and healthy controls. This finding could not only lead to the use of sIL-2R as a 
marker of inflammatory disease activity in CRPS but also to the use of sIL-2R during the 
diagnostic work-up of this disease. As per our knowledge, no study has yet been performed 
on this subject. Consequently, further studies are required to validate sIL-2R as a marker of 
inflammatory disease activity in CRPS and to establish a validated diagnostic cut-off value 
to differentiate CRPS from other chronic pain diseases (e.g. fibromyalgia) and autoimmune 
and auto-inflammatory disorders (e.g. rheumatoid arthritis).
While our findings indicate increased T-cell activity in CRPS, it is still unclear what 
subset of T-cells is being activated as sIL-2R is T-cell subset nonspecific and is thus measured 
during activation of different T-cell subsets (22).
Previous studies have tried characterizing changes in lymphocyte subsets in CRPS (20, 







numbers, lymphocyte subpopulations and T-helper 1/T-helper 2 (Th1/Th2) ratio in CRPS 
patients, fibromyalgia patients and healthy controls (20). They found a significant reduction 
of CD8+ T-lymphocytes in CRPS patients as compared to healthy controls (20).
In 2015, Osborne et al studied skin immune cell populations in long-standing CRPS 
and found no significant differences in overall immune cell infiltrates between CRPS af-
fected and unaffected limbs (21).
As stated previously, while our findings indicate increased T-cell activity in CRPS, we 
cannot specify which subset(s) of T-cells are active, making it difficult to relate our findings 
to the findings from the studies mentioned above (20, 21). Moreover, both studies used 
different methodologies to study involvement of T-cells (i.e. skin punch biopsies in the study 
by Osborne et al. and venous blood samples in the study by Kaufmann et al.) (20, 21). 
Furthermore, Osborne et al. compared the unaffected and affected extremity in CRPS pa-
tients (side to side comparison) while Kaufmann et al. looked at differences between CRPS 
patients, fibromyalgia patients and healthy controls (20, 21). As a consequence, comparison 
of our results to those of Kaufmann et al. or to those of Osborne et al. is rather meaningless 
(20, 21).
Further, the internal and external validity of this current study should be evaluated 
taking into account the potential incomparability of the experimental groups in terms of 
age, gender, past history and medication as demographic data and medical history were 
unavailable for the control group.
Finally, our study consists of a cross-sectional measurement of sIL-2R levels in CRPS 
patients and healthy blood bank donors. It would be interesting to prospectively study sIL-
2R levels during the course of this disease. This could increase our understanding on the role 
of T-cell activity in the onset and maintenance of CRPS.
Based on the findings of this study, we propose a role of T-cell-mediated inflammation 
as an underlying mechanism in the pathophysiology of CRPS. Our results are of consider-
able relevance as the involvement of T-cells in CRPS could lead to a better understanding 
of the rather complex pathophysiology of this disease. The findings of this study and the 
results of possible future research might lead to new therapeutic targets in the treatment of 
CRPS patients with (T-cell mediated) inflammation as an underlying mechanism of disease, 
thereby paving the way for new anti-inflammatory and/or immunomodulating therapies in 
the management of CRPS.
CoNCLuSIoN
The median sIL-2R level of CRPS patients was found to be significantly increased as com-





















































This finding could point towards a T-cell mediated inflammatory process in CRPS, 
which could pave the way for new anti-inflammatory therapies in the treatment of CRPS 
patients with (T-cell mediated) inflammation as their underlying mechanism of disease. 
However, the precise role of T-cells in the pathophysiology of CRPS has yet to be unraveled.
Furthermore, sIL-2R level seems to be a good discriminator between CRPS patients and 
healthy controls. CRPS is still a clinical diagnosis. Until now, no diagnostic test exists for 
monitoring inflammatory disease activity in CRPS. Based on our findings, sIL-2R could be 
a promising new marker to determine inflammatory disease activity in CRPS. However, this 
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Previously, we showed that serum soluble interleukin-2 receptor (sIL-2R) levels, a marker for 
T-cell activation, were higher in Complex Regional Pain Syndrome (CRPS) patients than 
in healthy controls, suggesting pathogenic T-cell activation in CRPS. Additionally, sIL-2R 
levels discriminated well between CRPS and healthy controls with a high sensitivity (90%) 
and specificity (89.5%), suggesting a possible role for sIL-2R in the diagnosis of CRPS. 
In order to further validate this marker in the diagnostic workup of CRPS, we conducted 
this prospective cohort study in which we determined sIL-2R levels in patients that were 
referred to our tertiary referral center with a suspicion of CRPS in a limb, and subsequently 
compared sIL-2R levels between the patients that were diagnosed with CRPS (CRPS group) 
and those who were not (no-CRPS group). A group of anonymous blood bank donors were 
used as a healthy control group. Furthermore, we explored the relationship between sIL-2R 
and CRPS disease severity using the CRPS severity score. Median sIL-2R levels of both the 
CRPS group (2809.0 pg/ml; Q3-Q1: 3913.0-1589.0) and no-CRPS group (3654.0 pg/ml; 
Q3-Q1: 4429.0-2095.5) were significantly higher than that of the control group  (1515.0 
pg/ml; Q3-Q1: 1880.0-1150.0): CRPS vs controls, p<.001; no-CRPS vs controls, p<0.001. 
Serum sIL-2R levels did not differ significantly between the CRPS and no-CRPS group. 
A statistically significant negative correlation was observed between sIL-2R levels and the 
CRPS severity score (rs= -0.468, p=0.024).  Our results confirm our previous findings of 
higher sIL-2R levels in CRPS patients than in healthy controls. We further showed that 
serum sIL-2R cannot differentiate between CRPS and other pain conditions of a limb in a 
tertiary referral setting. Interestingly, a negative correlation was found between sIL-2R and 
CRPS disease severity, this finding warrants further research into the relationship between 
















































Complex regional pain syndrome (CRPS) is characterized by continuous pain which is 
accompanied by various sensory, motor, vasomotor, sudomotor and trophic disturbances 
(1). The onset of CRPS is preceded by damage to the tissues of a limb, for example, due to 
fracture or surgery (2). If CRPS is left untreated, it can have incapacitating consequences not 
only on the function of the affected limb, but also on the social life of patients (3). However, 
appropriate treatment is often initiated too late due to a delay in diagnosis (4).
This diagnostic delay is mostly due to two reasons. First, the diagnosis of CRPS is still 
based on a set of relatively subjective criteria: the New International Association for the Study 
of Pain clinical diagnostic criteria for CRPS (1). Thus, the (early) diagnosis of CRPS cannot 
yet be established by objective diagnostic testing. Second, the pathophysiology of CRPS is 
complex and still incompletely understood; this lack of understanding creates skepticism 
among physicians on whether this disease exists (5, 6) and further leads to a general lack of 
awareness on the symptoms and signs of this disease.
Although the pathophysiology of CRPS is still incompletely understood, it has been 
established that it comprises of multiple disease mechanisms (7). Inflammation is recognized 
as one of the pathophysiological mechanisms contributing to CRPS. This inflammation 
may, in part, be related to dysregulation of the immune system associated with altered T-cell 
activity (8-10). Our group previously assessed T-cell activity in CRPS patients by measuring 
serum levels of the soluble interleukin-2 receptor (sIL-2R): a marker for T-cell activation 
(8, 11, 12). We found significantly higher serum sIL-2R levels in the CRPS group than in 
healthy controls, supporting the notion of pathological T-cell activation in CRPS (8). More-
over, serum sIL-2R level discriminated well between CRPS patients and healthy controls, 
with a high sensitivity (90%) and specificity (89.5%)  (8).
This last finding is especially noteworthy as it indicates that serum sIL-2R may represent 
a biomarker to facilitate the diagnosis of CRPS. Elevated serum sIL-2R levels are, however, 
not disease-specific as this is found in many different disease entities, including immune and 
rheumatic diseases, as well as malignancies (13). Yet, the potential diagnostic value of serum 
sIL-2R was recently demonstrated in a retrospective cohort study in patients suspected of 
sarcoidosis (14). On the basis of an established cut-off value, the sensitivity and specificity 
of serum sIL-2R for the detection of sarcoidosis was 88% and 85%, by far superior to 
angiotensin-converting enzyme (ACE; the classical biomarker for sarcoidosis with a sensitiv-
ity of 62% and specificity of  88%) (14). Therefore, we consider it of interest to further 
explore the potential application of serum sIL-2R measurement in establishing the diagnosis 
of CRPS. At this moment, biomarkers validated for use in the diagnosis of CRPS are not 
available. However, identification of potential diagnostic biomarkers could greatly aid in 







Previously, we determined serum sIL-2R levels only in CRPS patients and healthy 
controls and consequently, we could not draw conclusions on the role of serum sIL-2R in 
the diagnostic workup of CRPS (8). Therefore, in this current study, we examined whether 
serum sIL-2R can be used to differentiate CRPS from other pain conditions of a limb in 
patients referred to a tertiary referral center due to a suspicion of CRPS.
mateRIaLS aND methoDS
ethical approval
This study was conducted according to the principles of the Declaration of Helsinki and in 
accordance with the Medical Research Involving Human Subjects Act (WMO). The study 
was approved by the Medical Ethics Committee of Erasmus MC University Medical Center 
Rotterdam (MEC-2017-495). The trial was registered in the Netherlands Trial Registry 
(NTR7465).
Study design, recruitment and study population
This prospective cohort study was conducted at the Center for Pain Medicine (CPM) at 
Erasmus MC University Medical Center which is a teaching hospital located in Rotterdam, 
the Netherlands. The CPM is a tertiary referral center with CRPS being one of the fields of 
expertise. Patients are referred to our center by general physicians or other specialists such as 
orthopedic surgeons.
All patients referred to our center with a suspicion of CRPS in one limb were invited to 
participate in this study. Two weeks before their first outpatient clinic appointment, patients 
were approached by a study physician with both verbal and written information on the 
study. The patients could decide on the day of their appointment whether they wanted 
to participate in the study. Patients were informed that the results of this study would not 
influence the diagnosis or treatment of their disease. After obtaining informed consent, the 
inclusion and exclusion criteria described in table 1 were applied. Patients were included 
consecutively until the required sample size was reached. The inclusion period started in 
March 2018 and ended in August 2019.
Serum sIL-2R levels available from 101 anonymous healthy blood bank donors served 
as a reference for serum sIL-2R levels in the healthy population. Thus, the study population 
consisted of 3 groups: patients finally diagnosed with CRPS (CRPS group), patients finally 















































table 1 Inclusion and exclusion criteria applied in this study. Patients had to meet both the inclusion 
criteria and were excluded if they met any of the exclusion criteria.
Inclusion criteria exclusion criteria
Age ≥ 18 years History of an auto-inflammatory or autoimmune disease
Only one limb is affected Current or past (within the last six months) treatment with 
immunomodulating medication such as steroids or TNF-α inhibitors
Ill in the past two weeks or at the time of visit
Potential pregnancy or confirmed pregnancy
Study measurements and data collection
The following data were collected during the outpatient clinic appointment: age; duration 
of disease (i.e. duration of symptoms and signs); precipitating injury (i.e. initiating factor of 
symptoms and signs); affected limb; medication; intensity of pain at the moment of the visit 
and in the past 24 hours using an 11-point Numeric Rating Scale (NRS); and symptoms 
and signs recorded using the CRPS severity score- Database Form developed by Harden 
et al. along with the resulting CRPS severity score (CSS) (15) (table 2). Permission was 
received from N. Harden for use of the CRPS severity score-Database Form (15).  The study 
physicians followed the instructions of the CRPS severity score- Database Form to register 
symptoms and signs during physical examination. At the end of the appointment, one 5 
milliliter tube of venous blood was drawn for sIL-2R analysis.
table 2 Symptoms and signs assessed using the CRPS severity score- Database Form by Harden et al. 
(15)
Symptoms*1 Signs*2
Continuing, disproportionate pain Hyperalgesia to single pinprick
Allodynia or Hyperalgesia Allodynia
Temperature asymmetry Temperature asymmetry by palpation
Color asymmetry Color asymmetry
Sweating asymmetry Sweating asymmetry
Edema Asymmetric edema
Dystrophic changes Dystrophic changes
Motor abnormalities*3 Motor abnormalities*4
*1 Symptoms as reported by the patient. All symptoms are categorical variables and are registered as 
absent or present.
*2 Signs as observed during physical examination by the physician. All signs are categorical variables 
and are registered as absent or present.
*3 Motor abnormalities as reported by the patient: weakness, tremor, dystonia, decreased range of mo-
tion, myoclonus.
*4 Motor abnormalities as observed by the examiner: tremor/myoclonus, dystonia, decreased active 







Diagnosis of CRPS group and no-CRPS group
CRPS was diagnosed using the widely accepted New International Association for the Study 
of Pain Clinical Diagnostic Criteria for CRPS (1). All other diagnoses were established us-
ing appropriate and up-to-date guidelines and when needed, patients were referred to the 
appropriate specialty. The diagnoses of patients in the no-CRPS group were divided into 
the following categories: neuropathic pain syndromes, myofascial pain syndromes, vascular 
diseases, inflammatory conditions and psychiatric problems/disorders. These categories were 
derived from the differential diagnosis of CRPS as described in the article by van Eijs et al. 
(16).
sIL-2R analysis
Venous blood samples were centrifuged at 3000 rpm after collection and serum was subse-
quently isolated. Soluble IL-2R levels were measured using an enzyme linked immunosor-
bent assay (Human sCD25/sIL-2R ELISA kit, Besancon, Cedex, France) according to the 
manufacturer’s instructions at the diagnostic Laboratory Medical Immunology facility of 
Erasmus MC University Medical Center Rotterdam. The measurements were conducted 
under strict quality procedures (ISO15189).
Sample size calculation
Based on the results of our previous study (8), we chose a statistically detectable and clini-
cally relevant effect size (d) of 1.0 on serum sIL-2R level using an independent t-test. The 
power of the study (1-β) was set at 0.8, the allocation ratio at 0.25 and the two-sided level of 
significance (α) at 0.05. The required sample size computed by this method was 52.
Statistical analysis
Descriptive statistics were used to calculate the frequencies of categorical variables and to 
calculate measures of central tendency and variability of continuous variables. The Shapiro-
Wilk test was used to analyze whether continuous variables were normally distributed. Vari-
ables with a skewed distribution are reported in medians and interquartile ranges (Q3-Q1), 
otherwise means and standard deviations are used. The primary outcome parameter was the 
serum sIL-2R level in the CRPS group, no-CRPS group and healthy control group.
Depending on the shape of distribution, continuous variables were compared between 
two groups using either a two-sided independent t-test or a two-sided Mann-Whitney-U 
test. Comparison of continuous variables between more than two groups was conducted 
using either an ANOVA or a Kruskal-Wallis test, dependent on the shape of the distribution 
of the variable. Categorical variables were compared using the Fisher’s exact test.
A possible association in the CRPS group between sIL-2R levels and age, sIL-2R levels 
and duration of disease and sIL-2R levels and the CRPS severity score was explored using 















































the distribution of these variables. A possible association in the CRPS group between sIL-2R 
levels and gender was explored using a point-biserial correlation.
Where possible, data are presented in tables and graphs, such as box-and-whisper plots 
and scatterplots. For box-and-whisper plots that are created in SPSS, the box represents the 
interquartile range and the whiskers extend to the highest and lowest value in the data range 
which are no greater than 1.5 times the interquartile range. Circles in the box-and-whisker 
plots indicate outliers that are between 1.5 and 3 times the interquartile range. Analyses were 
performed using IBM SPSS Statistics 21. The alpha level for statistical significance was set 
at 0.05.
ReSuLtS
Figure 1 depicts the recruitment and inclusion of our study population. A total of 86 patients 
were approached to participate in this study. Twenty-nine patients did not participate in the 
study: one patient canceled the outpatient clinic appointment; one patient did not show up 
at the appointment; two patients had an incorrect referral; five patients declared, of their 
own accord, during the phone call that they have an autoimmune or auto-inflammatory 
disorder with or without use of immunomodulating medication; six patients were unwilling 
to participate in research; and fourteen patients were unreachable when called. Fifty-seven 
patients signed the informed consent form. Five patients were excluded after signing the 
form: two patients were excluded due to use of prednisolone; one patient did not have time 
to complete the outpatient visit; one patient backed out without further explanation and one 
patient was excluded because of a history of active psoriasis. This resulted in the required 
sample size of 52 patients for analysis.
Of the 52 patients, 23 patients (44%) were diagnosed with CRPS and 29 patients (56%) 
were diagnosed with other conditions (no-CRPS group). Of the no-CRPS group 7 patients 
(24.1%) were diagnosed with neuropathic pain syndromes, 17 (58.6%) with myofascial 
pain syndromes, 2 patients (6.9%)with inflammatory conditions and 3 patients (10.3%) 
had an unclear or unknown diagnosis. No diagnoses were made that could be categorized 
as vascular diseases or psychiatric problems/disorders. Full details of the no-CRPS group, 
including diagnoses that were made per category, can be found in table 3.
Patient characteristics such as age, gender, affected limb, precipitating injury and dura-
tion of disease were comparable among both the CRPS group and the no-CRPS group (table 
4). Use of medication was also comparable among both groups (table 5). Median pain scores 








Table 6 shows the proportion of symptoms and signs in each group recorded according 
to the CRPS severity score- Database Form (15). The prevalence of the following symptoms 
(i.e. subjective symptoms reported by patients) was significantly higher in the CRPS group 
than in the no-CRPS group: continuing pain, color asymmetry and decreased active range 
of motion of the affected limb. The prevalence of the following signs (i.e. objective signs 
observed by the physician) was significantly higher in the CRPS group than in the no-CRPS 
group: hyperalgesia to pinprick; allodynia and its corresponding subcategories; temperature 
asymmetry, with all affected CRPS patients having a cooler affected limb; color asymme-
try and its corresponding subcategory ‘red’; sweating asymmetry, with all affected CRPS 
patients experiencing increased sweating on the affected side; and asymmetric edema. The 
mean CRPS severity score was significantly higher in the CRPS group than in the no-CRPS 
group (CRPS 11.4 (sd=2.2) versus no-CRPS 8.1 (sd=1.9), p<0.001).
 




















































healthy controls 101 1515.0 (1880.0-1150.0)
CRPS group 23 2809.0 (3913.0-1589.0)
No-CRPS group 29 3654.0 (4429.0-2095.5)
Neuropathic pain syndromes*1 (n, % no-CRPS group) 7 (24.1) 4170.0 (5203.0-2050.0)
myofascial pain syndromes*2 (n, % no-CRPS group) 17 (58.6) 3529.0 (4253.5-2150.5)
Inflammation*3 (n, % no-CRPS group) 2 (6.9) N/A
unknown*4 (n, % no-CRPS group) 3 (10.3) N/A
*1 Neuropathic pain syndromes: peripheral neuropathy (n=5); Cervical dermatomal pain (n=1); Ra-
dicular pain (n=1).
*2 Myofascial pain syndromes: post-fracture pain and osteoarthritis (n=1); osteoarthritis (n=1); disuse 
(n=1); myalgia (n=1); disability and impairment of hand related to fracture as diagnosed by plastic sur-
geon (n=2); shin splints (n=1); subacromial pain syndrome (n=1); unspecified pain of the shin (n=1); 
suspected patellofemoral pain syndrome (n=1); suspected clenched fist syndrome (n=1); pain related 
to healing process after trauma (n=4); post-surgical pain (n=2).
*3 Inflammation: osteomyelitis (n=1); arthritis of the wrist (n=1). Median sIL-2R levels were not cal-
culated due to the size of the group.
*4 Median sIL-2R levels were not calculated due to the size of the group.
table 4 Patient demographics and general characteristics of the no-CRPS and CRPS group.
Demographics and characteristics No CRPS (n=29) CRPS (n=23) Significance
age in years (median, (Q3-Q1)) 43.0 (55.5-27.5) 37.0 (55.0-28.0) NS
Duration of disease in months 
(median, (Q3-Q1))










Right upper limb (n,%)
Left upper limb (n,%)
Right lower limb (n,%)

































The median sIL-2R levels of both the CRPS group (2809.0 pg/ml; Q3-Q1: 3913.0-
1589.0) and no-CRPS group (3654.0 pg/ml; Q3-Q1: 4429.0-2095.5) were significantly 
higher than the median sIL-2R level of the control group  (1515.0 pg/ml; Q3-Q1: 1880.0-
1150.0): CRPS group vs control group p<.001 and no-CRPS group vs control group 
p<0.001. Serum sIL-2R levels did not differ significantly between the CRPS group and 
no-CRPS group (Figure 2 and Table 3).
Of the no-CRPS group, both the neuropathic-pain-syndromes group (4170.0 pg/ml; 
Q3-Q1: 5203.0-2050.0) and myofascial-pain-syndromes group (3529.0 pg/ml; Q3-Q1: 
4253.5-2150.5) had median sIL-2R levels that were significantly higher than the median 
sIL-2R level of healthy controls (1515.0 pg/ml; Q3-Q1: 1880.0-1150.0): neuropathic-
pain-syndromes group versus control group p<0.001 and myofascial-pain-syndromes group 
versus control group, p<0.001. There was no significant difference in the distribution of 
sIL-2R levels between the neuropathic-pain-syndromes group, myofascial-pain-syndromes 
group and the CRPS group (Figure 3 and Table 3).
Within the CRPS group, a statistically significant negative correlation existed between 
serum sIL-2R levels and the CRPS severity score (rs= -0.468, p=0.024, Figure 4). No as-
sociation was found between serum sIL-2R level and age, gender and disease duration in the 
CRPS group.
table 5. Medications being used at the time of visit at the outpatient clinic center
medication No-CRPS (n=29) CRPS (n=23) Significance
Paracetamol (n,%) 10 (34.5) 9 (39.1) NS
NSaIDs*1 (n,%) 10 (34.5) 5 (21.7) NS
opioids (n,%) 5 (17.2) 8 (34.8) NS
antidepressants (n,%) 3 (10.3) 6 (26.1) NS
anti-epileptics (n,%) 3 (10.3) 6 (26.1) NS
Calcium Channel 
Blockers (n,%)




vitamin C (n,%) 6 (20.7) 3 (13.0) NS
fluimucil or N-acetyl 
cysteine (n,%)
0 1 (4.3) N/A
DmSo*2 (n,%) 2 (6.9) 0 N/A
















































table 6 CRPS severity score-Database Form: presence of symptoms and signs of CRPS in each group
Symptoms No CRPS (n=29) CRPS (n=23) Significance
NRS at time of visit (median, 
Q3-Q1)
7.0 (8.0-3.0) 7.0 (8.0-6.0) NS
NRS 24 hours before visit 
(median, Q3-Q1)
7.5 (8.0-6.3) 8.0 (8.0-7.0) NS













































Sweating asymmetry 12 (41.4) 14 (60.9) NS









































Signs No CRPS (n=29) CRPS (n=23) Significance











































table 6 CRPS severity score-Database Form: presence of symptoms and signs of CRPS in each group 
(continued)






















Increased on affected side




























































CRPS severity score (mean, sd) 8.1 (1.9) 11.4 (2.2) P<0.001
*1Weakness 1/5: flicker of movement
*2Weakness 2/5: movement with gravity
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figure 2 Boxplot of the median sIL-2R levels in the no-CRPS group (3654.0 pg/ml; Q3-Q1: 4429.0-
2095.5), the CRPS group (2809.0 pg/ml; Q3-Q1: 3913.0-1589.0) and the control group (1515.0 pg/
ml; Q3-Q1: 1880.0-1150.0): CRPS vs controls p<.001 and no-CRPS vs controls p<0.001
 
 
figure 3 Boxplot of median sIL-2R levels in the neuropathic-pain-syndromes group (4170.0 pg/ml; 
Q3-Q1: 5203.0-2050.0), the myofascial-pain-syndromes group (3529.0 pg/ml; Q3-Q1: 4253.5-
2150.5), the CRPS group (2809.0 pg/ml; Q3-Q1: 3913.0-1589.0) and the group of healthy controls 
(1515.0 pg/ml; Q3-Q1: 1880.0-1150.0): neuropathic pain syndromes versus controls p<0.001 and 










Figure 3 Boxplot of median sIL-2R levels in the neuropathic-pain-syndromes group (4170.0 pg/ml; Q3-Q1: 
5203.0-2050.0), the myofascial-pain-syndromes group (3529.0 pg/ml; Q3-Q1: 4253.5-2150.5), the CRPS 
group (2809.0 pg/ml; Q3-Q1: 3913.0-1589.0) and the group of healthy controls (1515.0 pg/ml; Q3-Q1: 
1880.0-1150.0): neuropathic pain syndromes versus controls p<0.001 and myofascial pain syndromes versus 
controls, p<0.001. 
 
Figure 4 Scatter plot showing the correlation between serum sIL-2R level and CRPS severity score in CRPS 




















figure 4 Scatter plot showing the correlation between serum sIL-2R level and CRPS severity score in 
CRP  patients: rs= -0.468, p=0.024
DISCuSSIoN
So far, objective diagnostic tests to diagnose CRPS are not available. Th is lack of objec-
tive tests hampers early diagnosis and timely initiation of appropriate therapies (17). Based 
on fi ndings from our previous study in which sIL-2R levels were found to be signifi cantly 
higher in CRPS patients than in healthy controls (8), we conducted this current study in 
which we investigated whether serum sIL-2R could be used to help establish the diagnosis 
CRPS in patients who were referred to a tertiary referral center with pain in a limb that 
was suspected to be caused by CRPS. To our knowledge, this is the fi rst study assessing the 
diff erentiating capacity of serum sIL-2R in CRPS. Our results indicate that serum sIL-2R is 
not useful for diff erentiating CRPS from other pain conditions of a limb in patients referred 
with a suspicion of CRPS to a tertiary referral center.
One of the main explanations why serum sIL-2R may not be useful in diff erentiating 
CRPS from other pain conditions of a limb may be that altered T-cell activity occurs in 
various diseases that are part of the initial diff erential diagnosis of CRPS. For example, there 
are diseases in the diff erential diagnosis of CRPS that have been proven to involve T-cell 
activation and have been shown to have elevated sIL-2R levels, such as rheumatoid arthritis 
(13, 18).  Recently, carpal tunnel syndrome (CTS) —which also needs to be considered in 
the diff erential diagnosis of CRPS of the upper limb — was shown to be associated with 
elevated percentages of central and eff ector memory CD4+ T-cells which is suggestive of 















































serum sIL-2R levels may be elevated in CTS patients as well, although data on this is lacking 
so far. There is also evidence that altered T-cell activity may play a role in (the development 
of ) neuropathic pain (20, 21). It is thus plausible, that there is altered T-cell activity in the 
various diseases that make up the differential diagnosis of CRPS, thereby diminishing any 
differentiating power serum sIL-2R may have in the diagnosis of CRPS. Moreover, as stated 
in the introduction, elevated serum sIL-2R levels are not disease-specific as elevated levels of 
sIL-2R can be found in many different diseases (12, 13).
In this study, we have confirmed our previous finding of elevated serum sIL-2R levels 
in CRPS, indicating that T-cell activation is involved in the pathogenesis of CRPS (8-10). 
It was further observed that the group of neuropathic pain syndromes was also associated 
with elevated serum sIL-2R levels, indicating that T-cell activation is likely to be involved 
in these pain syndromes. In line with this, recent observations in animal models support 
an important role for T-cells in (the development of ) neuropathic pain (20, 21). We also 
found significantly higher sIL-2R levels in the myofascial-pain-syndromes group than in the 
group of healthy controls. This may be related to the various diagnoses we categorized into 
this group. For reasons of simplicity, we categorized diseases as myofascial pain syndromes if 
they were not considered neuropathic or ‘classically inflammatory’ by nature. However, it is 
not unthinkable that certain diseases we classified in this group, such as osteoarthritis, could 
reveal increased sIL-2R levels (table 3) (22). Nevertheless, studies in larger cohorts should 
separately explore the contribution of T-cells to the various diseases categorized into the 
group of myofascial pain syndromes.
Interestingly, we further found a statistically significant negative correlation between 
sIL-2R levels and the CRPS severity score in our CRPS patients. We propose three explana-
tions for this negative correlation in our cohort of CRPS patients. First, it is possible that 
serum sIL-2R level reflects T-cell driven inflammatory disease activity (the intensity of the 
inflammatory process) rather than disease severity (the impact of the disease activity on the 
limb) in CRPS. Such would indicate that serum sIL-2R level measured in CRPS may be 
strongly related to the phase of disease. Patients in the acute phase of CRPS, often present 
with the warm subtype of CRPS (2, 23). As the disease progresses and becomes chronic, 
most patients undergo a change from a warm (acute) subtype to a cold (chronic) subtype 
(24). It is thought that this subtype transition is caused by a change in active underlying 
pathophysiological mechanisms during the course of this syndrome. For example, inflam-
matory mechanisms seem to be most prominent in the warm (acute) CRPS subtype and 
seem to diminish as the disease progresses (24). However, (tissue) damage inflicted by the 
early inflammatory phase may persist and even worsen because of other pathophysiological 
mechanisms that gain the upper hand. Considering that all CRPS patients in this study had 
chronic CRPS, it is possible that in this group of chronic CRPS patients, T-cell mediated 
inflammatory disease activity, and thus sIL-2R level, has diminished over time while the 







interesting to test this hypothesis with serial measurements of sIL-2R in a prospective cohort 
of acute CRPS patients.
Second, this negative correlation may be explained by an immunosuppressive biological 
function of sIL-2R. The sIL-2R is the circulating form of the α-chain of the membrane-bound 
high-affinity trimeric interleukin-2 (IL-2) receptor. IL-2 is an important regulatory cytokine 
for the activation, proliferation, differentiation and survival of different T-cell subsets (12, 
25, 26). It has been suggested that circulating sIL-2R competes for available IL-2 and may 
limit activation and proliferation of T-lymphocytes by sequestration of available IL-2 (12, 
25, 27-31). It has further been proposed that sIL-2R presents IL-2 to CD4+T-helper cells, 
thereby inducing T-cell differentiation towards anti-inflammatory T-regulatory cells (Tregs) 
instead of pro-inflammatory Th1 or Th17 cells (25, 32). Considering that the discovered 
negative correlation suggests a higher sIL-2R is associated with less disease severity, it can be 
hypothesized that sIL-2R may have an immunosuppressive, and thus protective, biological 
function in CRPS. This idea is partially supported by the findings in the study by Heyn et 
al. in which the authors found a significantly lower percentage of pro-inflammatory Th17 
cells, a lower Th17/Tregs ratio and a significantly higher proportion of anti-inflammatory 
CD39+Tregs in a group of CRPS patients, suggesting an anti-inflammatory T-cell shift in 
CRPS (9).
Third, the negative correlation may reveal an inability of our clinical observations to 
objectify a possible T-cell mediated inflammatory pathology and the related disease activity 
and severity in CRPS. This inability of our clinical observations to reflect an underlying 
pathology could explain the discrepancy between biochemical changes and clinical findings 
that is often found in CRPS.
Thus, although in our current study serum sIL-2R seems to lack diagnostic value when it 
comes to differentiating CRPS from other pain conditions of a limb with a similar presenta-
tion, it seems that this marker may have a potential role in the monitoring of disease activity 
and/or severity of CRPS. This warrants future research in which the relationship between 
serum sIL-2R levels and disease activity and severity of CRPS are explored.
We made two interesting observations in this study: first, our current study population 
had a relatively long disease duration; and second, at the time of measurement, patients who 
suffered from temperature changes all had a cool limb. Our Center for Pain Medicine is a 
tertiary referral center and it seems that the cases that are referred to us are usually the cases 
that are refractory to therapy and can be considered to have chronic (cold type) CRPS based 
on the disease duration. Thus, a limitation of our study is that there may be a referral bias in 
the study population resulting in a patient sample that may not be completely representative 
of the general CRPS patient population. Therefore, it is not unlikely that if this study were 
to be replicated in another setting such as a secondary hospital where patients are seen at an 
earlier stage and/or with a warm limb, it might return different results. We therefore suggest 















































future research should also focus on measuring other inflammatory markers in CRPS, for 
example, cytokines or other soluble surface molecules secreted from activated immune cells.
Another limitation of our study is that the current sample size was calculated based on 
the effect-size which was derived from our first study in which we investigated whether there 
was a difference in serum sIL-2R levels between CRPS patients and healthy controls (8). 
The observed effect-size from this previous study was rather large and may have led to an 
underestimation of the required sample size for the current study. Therefore, this study may 
have been underpowered for the primary outcome: the difference between sIL-2R levels in 
the CRPS group and no-CRPS group. Furthermore, we chose not to conduct corrections for 
multiple testing with regard to the secondary outcomes as it may have barred the discovery 
of potential associations that could be of interest to explore in future research.
Despite the limitations mentioned above, we believe that the greatest strength of our 
study is the selection of the study population. All patients included in this study were sus-
pected of having CRPS. Therefore, our no-CRPS group consisted of various diseases that 
can display the same symptoms and signs as CRPS in a limb. Thus, our study design closely 
reflects clinical practice, especially in a tertiary care setting, and could be used as a model for 
replication studies.
CoNCLuSIoN
In summary, we conclude that serum sIL-2R cannot be used in a tertiary referral setting to 
differentiate CRPS from other pain conditions of a limb in patients referred with a suspicion 
of CRPS. Our current findings confirm the findings from our previous study in which serum 
sIL-2R levels are shown to be higher in CRPS patients than in healthy controls, suggesting 
a role for pathogenic T-cell activation in CRPS (8).
Although serum sIL-2R may not be useful in establishing the diagnosis CRPS, future 
studies should focus on replicating this study in a primary and/or secondary care setting and 
should further focus on exploring the relationship between sIL-2R and (T-cell mediated) 
disease activity and disease severity in CRPS. These explorations could reveal a possible role 
for sIL-2R as a biomarker for disease activity and/or severity in CRPS and could further 
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SummaRy of thIS theSIS
The aim of this thesis was threefold: 1) to explore the need for diagnostic and therapeutic 
biomarkers in Complex Regional Pain Syndrome (CRPS); 2) to study the role of the T-cell-
specific sIL-2R and macrophage-specific sCD163 as potential biomarkers in CRPS; and 3) 
to address (recent) concerns that CRPS is not a distinct diagnostic entity. To this end, this 
thesis was divided into three parts with each part exploring one of the three sub-aims.
In Part 1 (chapters 1, 2 and 3), the need for diagnostic and therapeutic biomarkers in 
CRPS was explored. In Chapter 1, the introduction of this thesis, the importance of bio-
marker research in CRPS is explained and the aim of this thesis was outlined. In chapter 2, 
a concise and up-to-date overview on the diagnosis and management of CRPS is presented 
which also highlights the lack of objective tests to diagnose and manage this syndrome. In 
Chapter 3, an extensive review is given on the various potential biomarkers of inflammation 
that have been identified in CRPS and their current place in the diagnosis and management 
of CRPS (chapter 3).
In Part 2 (chapters 4, 5 and 6) we build on the findings from part 1 through hands-on in-
vestigation of two potential immunological biomarkers in CRPS: the T-cell-specific soluble 
interleukin-2 receptor (sIL-2R) and the macrophage-specific soluble CD163 (sCD163). In 
chapter 4, we showed that levels of sIL-2R were significantly increased in CRPS patients 
suggesting pathological activation of T-lymphocytes. In addition, this marker had a high dif-
ferentiating capacity between CRPS patients and healthy controls. In chapter 5, we explored 
whether this marker could be used to differentiate patients with CRPS from patients with 
other pain conditions of a limb in a tertiary referral setting. We found that this marker 
could not differentiate between these two groups, however, that there still may be a role for 
this marker in the monitoring of inflammatory disease activity and/or severity in CRPS. In 
Chapter 6, we measured levels of the macrophage-specific sCD163 in CRPS patients and a 
group of healthy controls and found that this marker was significantly higher in the CRPS 
group, suggesting activation of local tissue-resident macrophages and thus the monocyte-
macrophage system in CRPS.
Finally, in Part 3 (chapters 7 and 8), we addressed recently published critical articles that 
claimed that CRPS is not a distinct diagnostic entity (Chapter 7). The arguments presented 
in these critical articles are refuted in a review article using the extensive empirical literature 
available on CRPS. The need to address these accounts stems from concerns that these 
critical articles may be harmful to patients by encouraging dismissal of their CRPS signs and 
symptoms and further leading to patients feeling invalidated and misunderstood. Moreover, 
they may lead to appropriate treatment being withheld and may jeopardize recovery of 
patients. It becomes clear that the level of evidence for the arguments used to argue against 







a grain of salt. Part 3 ends with this current chapter, in which we summarize the major 
findings from this thesis and make recommendations for future research.
tyING It aLL toGetheR
Complex regional pain syndrome is a syndrome that is usually preceded by tissue injury to 
the affected limb, for example due to trauma, fracture, or surgery (1, 2). It is characterized 
by continuous pain, that is accompanied by sensory, vasomotor, sudomotor/edema, and 
motor/trophic disturbances (3). The diagnosis CRPS is made using the new International 
Association for the Study of Pain clinical diagnostic criteria for CRPS (3). There is currently 
no diagnostic test available to diagnose this syndrome and diagnostic tests are mainly used 
to exclude other diagnoses in the differential diagnosis of CRPS. It is advised to conduct 
treatment in a mechanism based manner, i.e., treatment should target the prominent under-
lying pathophysiological mechanisms in each CRPS case. If treatment is not initiated in a 
timely manner, CRPS can lead to a debilitating loss of function of the affected limb and can 
severely impact the quality of life of patients (4, 5).
Early diagnosis and therapy in CRPS are, however, hampered by the fact that there are 
no objective tests available to diagnose this syndrome, nor are their objective tests available 
to identify the underlying pathophysiological mechanisms to subsequently manage this syn-
drome. The demand for these objective tests can be met by researching potential clinical and 
biochemical biomarkers of the various identified pathophysiological mechanisms in CRPS. 
Mechanisms that have been identified in CRPS are inflammation (neurogenic, immune, 
neuroinflammation), central and peripheral sensitization, altered sympathetic nervous sys-
tem function, changes in circulating catecholamines, brain plasticity changes, contribution 
of genetic factors and psychological factors (3, 6).
Various articles, both original and review articles, have been published indicating po-
tential clinical and biochemical biomarkers of these mechanisms in CRPS (6, 7). The main 
setback is that most of these biomarkers have not yet been validated in CRPS, nor for the 
diagnosis nor for the management of this syndrome. It is, however, clear that because of 
the multi-mechanism pathophysiology of CRPS, not one biomarker will be available to 
diagnose or manage this syndrome. It is likely that in the future, a panel of biomarkers, be it 
clinical and/or biochemical, will be used to diagnose and manage this syndrome.
In this thesis, we focused on the role of biomarkers of inflammation, especially due 
to immune dysregulation, in CRPS. Inflammation is an important pathophysiological 
mechanism in CRPS, both for the onset and maintenance of this syndrome. Inflammation 
in CRPS seems to originate from three sources: neurogenic inflammation, neuroinflam-
mation and inflammation due to dysregulation of the immune system (6). The latter has 











innate and adaptive immune system have been shown to be dysregulated in CRPS (8). An 
example of dysregulation of the innate immune system is the finding that local levels of 
the pro-inflammatory cytokines tumor necrosis factor (TNF)-α and interleukin(IL)-6 are 
increased in CRPS affected extremities (9). An example of dysregulation of the adaptive im-
mune system is the higher prevalence of various autoantibodies that has been found in CRPS 
patients (10-13). Thus, both the innate and adaptive immune system represent interesting 
targets for biomarker research in CRPS.
In this dissertation, two new biomarkers of inflammation in CRPS are studied and pre-
sented: soluble IL-2R as a marker for T-cell activity and  thus dysregulation of a component 
of the adaptive immune system; and soluble CD163 as a marker for tissue-resident macro-
phage activation and thus dysregulation of a component of the innate immune system.
The soluble interleukin-2 receptor is an easily measurable systemic marker for T-cell 
activation (14, 15). Increased levels of this marker have been found in diseases in which T-
cell activity is centrally involved, such as rheumatoid arthritis and sarcoidosis, and have been 
shown to correlate with disease activity in these diseases (16-21). Furthermore, the diagnos-
tic value of sIL-2R was recently demonstrated for sarcoidosis in a large retrospective study: 
the sIL-2R had a sensitivity of 88% and specificity of 85% for the detection of sarcoidosis, 
which is by far superior to the classical diagnostic biomarker angiotensin-converting enzyme 
(ACE; sensitivity 62%, specificity 88%) (22). In CRPS, significantly higher levels of sIL-2R 
were found than in healthy controls, indicating pathological activation of T-cells in CRPS 
patients (23). The sIL-2R, however, showed no discriminative capacity between patients 
with CRPS and patients who were initially suspected of having CRPS but were diagnosed 
with another (pain)condition (24). This was unsurprising as most of the syndromes and 
diseases that make up the differential diagnosis of CRPS (25) have been shown to have 
altered T-cell activity (24).
Interestingly, sIL-2R had a statistically significant negative correlation with CRPS disease 
severity in our CRPS group (24). This negative correlation led us to hypothesize that sIL-2R 
may be a suitable marker for inflammatory disease activity (the intensity of the inflammatory 
process) and not disease severity (the impact of disease activity on the affected limb) in 
CRPS. In addition, this would also indicate that serum sIL-2R level may be related to the 
phase of disease it is measured in. In the acute phase of CRPS, patients often present with 
a warm CRPS subtype which is characterized by the classic signs of inflammation, such as 
redness, swelling, warmth, edema and loss of function of the affected limb (1, 2, 26). As 
the syndrome progresses and transitions into the chronic phase, a majority of the patients 
experience a transition from a warm (acute) subtype to a cold (chronic) subtype which is 
characterized by a less edematous, cold, and blue/pale limb (26). This transition in subtypes 
is thought to be caused by a transition in active pathophysiological mechanisms during the 
course of this syndrome. For example, it appears that inflammatory mechanisms are most 







usually observed (26). During the course of this syndrome, these inflammatory mechanisms 
seem to diminish, however, the (tissue) damage caused by these inflammatory mechanisms 
persists and may even worsen due to other pathophysiological mechanisms gaining the up-
per hand.
Based on this transition in pathophysiological mechanisms and the negative correlation 
between sIL-2R and CRPS disease severity, we propose a disease-model for the relationship 
between T-cell mediated inflammatory disease activity and CRPS disease severity based on 
duration of CRPS. Figure 1 illustrates this disease-model in which as CRPS progresses, 
T-cell mediated inflammatory disease activity — and thus sIL-2R— diminishes over time, 
while (tissue) damage caused by this inflammatory activity — the CRPS disease severity 
— persists, and may even worsen due to other pathophysiological mechanisms gaining the 
upper hand. In our study in Chapter 5 (24), all patients had chronic CRPS with a median 
syndrome duration of 26 months. The median level of sIL-2R in this group was lower than 
that of the CRPS group described in Chapter 4 which had a median syndrome duration 
of 11 months (23) and can thus be considered to have a relatively short (acute) duration 
of CRPS. Therefore, based on this careful observation and based on the proposed disease-
model hypothesis, it is conceivable that, T-cell mediated inflammatory disease activity, and 
thus sIL-2R level, diminishes over time. In line with this notion that sIL-2R may represent 
disease activity in CRPS, serum sIL-2R has previously been shown to be a marker of dis-
ease activity in several immune and rheumatic diseases, including sarcoidosis, rheumatoid 
arthritis and IgG4-related disease (16, 18, 20, 27). It would be interesting to test this disease-
model hypothesis with serial measurements of sIL-2R in a prospective cohort of acute CRPS 
patients. It is clear, however, that T-cells, and thus the adaptive immune system, are involved 
in the pathophysiology of CRPS and future research should focus on determining in which 
phase T-cells are active in CRPS so that appropriate therapies such as steroids can be started 
in a timely manner.
The other biomarker assessed in this thesis was sCD163, which is a marker for tissue-res-
ident macrophage activation, and by default activation of the monocyte-macrophage system 
and thus innate immune system in CRPS. Soluble CD163 is the circulating, extracellular 
portion of the CD163 membrane receptor for haptoglobin-hemoglobin complexes which is 
solely expressed on monocytes and macrophages. Soluble CD163 is enzymatically cleaved 
from the macrophage surface during activation by various pro-inflammatory stimuli (28-30) 
and is considered to be a useful biomarker of macrophage activation in various inflammatory 
diseases, such as macrophage activation syndrome, sepsis, liver disease and obesity (28, 31, 
32).This marker is also easily measurable in serum using a validated ELISA system. In our 
group of CRPS patients, we found that serum levels of sCD163 were significantly higher 
than in healthy controls, suggesting activation of tissue-resident macrophages in CRPS.
Interestingly, sCD163 also correlated negatively with CRPS disease severity, although 











tion, there was a significant positive correlation between sIL-2R and sCD163 in the CRPS 
group. This latter finding suggests simultaneous activation of the monocyte-macrophage 
and T-cell system in CRPS. While the use of sCD163 in the diagnosis and management of 
CRPS still needs to be validated in further studies, we can possibly explain the place of this 
marker in the diagnosis and management of CRPS by placing it in our pathophysiological 
model (Figure 1, see red bar indicating other inflammatory mechanisms). It is possible that, 
as with sIL-2R, sCD163 represents inflammatory disease activity and not disease severity in 
CRPS and the level of this marker may differ during different phases of this disease. Further, 
it is also possible, seeing that  a statistically insignificant, weak downhill correlation was 
found between sCD163 and CRPS disease severity, that the local macrophage system, and 
thus innate immune system, remains active for longer during the biological course of this 
syndrome, thereby, running somewhat parallel to the disease course and contributing, at 
least partially, to the disease severity in later phases of the syndrome. This is indirectly sup-
ported by previous findings by our group in which patients with the cold (chronic) CRPS 
subtype were shown to have local, i.e. skin blister fluid, TNF-α levels that did not differ from 
patients with the warm (acute) CRPS subtype (33). Serial measurements of sCD163 in a 
cohort of acute CRPS patients are needed to test this hypothesis.
Taken together, our findings show that there is pathological activation of both the 
monocyte-macrophage system and T-cell system in CRPS and thus a dysregulation of the 
innate and adaptive immune system in this syndrome. Serial measurements of sIL-2R and 
sCD163 in a prospective cohort of acute CRPS patients are needed to identify the place of 
these markers in the diagnosis and/or management of CRPS.
Ultimately, the pathophysiology of CRPS  is a confluence of various mechanisms rang-
ing from inflammation to endothelial dysfunction. Therefore, it is unlikely that there will 
ever be one biomarker that will be specific for CRPS, rather, in the future, multiple clinical 
and/or biochemical biomarkers will be used to assess which mechanisms are prominent in 
each CRPS case. However, the crux in forming such a biomarker panel still is the incom-
plete understanding of the pathophysiology of CRPS. Until the pathophysiology of CRPS 
becomes completely clear, numerous published and unpublished studies on CRPS are and 
will be focused on trying to understand the pathophysiological basis of this syndrome and 
subsequently on trying to objectify its diagnosis, and ultimately legitimizing its existence, 
possibly even as a disease.
LImItatIoNS of thIS theSIS aND 
ReCommeNDatIoNS foR futuRe ReSeaRCh
This thesis is not without its limitations. First, most of the conducted studies are cross-







and sCD163 during the biological course of this syndrome. Future studies conducting serial 
measurements of these markers in a cohort of acute CRPS patients, for example right after 
fracture, are warranted to assess not only the level of these markers in the acute phase, but 
also the role of T-cells and macrophages during the course of this syndrome. Second, there 
are various other inflammatory biomarkers that warrant testing in CRPS, this thesis focused 
on only two soluble markers of T-cell activation and macrophage activation. However, 
the choices for biomarker research are in some way limitless and both soluble and cellular 
markers for inflammation can be tested in future research. Third, the patient population in 
the studies in this thesis may not be representative of the whole CRPS population as the 
majority of patients had what can be considered chronic (cold) type CRPS. This was mainly 
related to the fact that our outpatient clinic center is a tertiary referral center which receives 
the most complex CRPS cases with a long duration of disease. Therefore, future research 
should focus on replicating this research in a primary and/or secondary care setting in which 
patients in the warm (acute) phase of CRPS are also included.
CoNCLuSIoNS fRom thIS theSIS
CRPS is a multi-mechanism syndrome and diagnosis and management should be focused on 
assessing and treating the mechanisms that are prominent in each CRPS case. Inflammation 
is a prominent mechanism especially in the early phase of CRPS, however, no inflammatory 
biomarkers have yet been validated to assess the level of inflammatory disease activity and 
severity in CRPS.
Serum levels of the soluble interleukin-2 receptor and soluble CD163 are increased in 
patients with CRPS indicating activation of both the T-cell system and macrophage system, 
respectively, in CRPS. These findings further support the notion that both the innate and 
adaptive immune system play a role in CRPS pathophysiology. Soluble IL-2R cannot be 
used in a tertiary referral setting to diagnose CRPS from other pain conditions of a limb, 
however, this marker may have a role in the assessment of inflammatory disease activity 
in CRPS. The latter is yet to be determined in future research. The value of sCD163 as a 
biomarker of diagnosis and management in CRPS is yet to be determined in future research.
Although there is skepticism surrounding the existence of CRPS, the amount of evi-
dence supporting the existence of this syndrome and the level of this evidence significantly 
outweigh the arguments presented in recently published (pseudoscientific) articles sug-
gesting this syndrome is fabricated. Therefore, this skepticism might even be considered to 
be misplaced. Patients with CRPS deserve to be heard and taken seriously regarding their 
symptoms and signs and future research on this syndrome should continue to unravel its 






















figure 1 Hypothetical model of the relationship between T-cell mediated inflammatory disease activ-
ity and CRPS disease severity: as CRPS progresses, T-cell mediated inflammatory disease activity — 
and thus sIL-2R— diminishes over time, while (tissue) damage caused by this disease activity— the 
CRPS disease severity — persists, and may even worsen. Based on current understandings, inflamma-
tory pathophysiological mechanisms seem to be most prominent in the warm (acute) CRPS subtype 
and seem to diminish as the syndrome progresses (26), however, (tissue) damage from these inflamma-
tory pathophysiological mechanisms may persist and possibly worsen due to other pathophysiological 
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Chapter 1 - General introduction
Chapter 1 introduces the rationale and aim of this thesis which is broadly to 1) highlight the 
need for biomarker research in Complex Regional Pain Syndrome (CRPS) and 2) address 
present skepticism on the existence of this syndrome. CRPS is still diagnosed using relatively 
subjective clinical criteria and there is no diagnostic test available yet to diagnose this disease. 
This subjectivity leads not only to a delay in diagnosis, but also to skepticism on the existence 
of this syndrome, both being issues which could be harmful to patients suffering from this 
debilitating condition. The identification of diagnostic (and therapeutic) biomarkers in 
CRPS would not only add an objective component to the diagnostic workup of CRPS, 
but also facilitate earlier identification and treatment of this syndrome. Although the exact 
pathophysiology of CRPS is yet to be established, it is now generally accepted that inflam-
mation is an important mechanism not only in the onset, but also in the maintenance of 
CRPS. Therefore, inflammation is an interesting target for biomarker research in CRPS and 
the role of inflammatory biomarkers, especially for T cell and tissue-resident macrophage 
activity, in the diagnosis and management of CRPS is explored.
Chapter 2 - Complex Regional Pain Syndrome: diagnosis and treatment
In this chapter, a concise overview is given of the current understandings on the pathophysi-
ology of CRPS and present recommendations for the diagnosis and treatment of CRPS are 
reviewed. Pathophysiological mechanisms that are discussed are inflammation, neurogenic 
inflammation, autoimmunity, ischaemia-reperfusion injury, genetic involvement, cortical 
reorganization, small fibre neuropathy and psychological factors. The cornerstones for 
diagnosis, which are history taking and physical examination, are discussed. Treatment is 
recommended to be conducted in a mechanism-based manner. Treatments that are discussed 
are anti-inflammatory drugs, analgetics/co-analgetics, vasodilators, muscle relaxants/spas-
molytics, psychological intervention and invasive treatments.
Chapter 3 - highlighting the role of biomarkers of inflammation in the 
diagnosis and management of Complex Regional Pain Syndrome
In this chapter, the role of inflammation in the multi-mechanism pathophysiology of CRPS 
is discussed and the application of potential biomarkers of inflammation in the diagnosis and 
management of this syndrome is highlighted. The reviewed biomarkers are divided into local 
biomarkers (TNF-α, IL-6, Tryptase, Mast cell numbers) and systemic biomarkers (CGRP, 
SP, CD14+CD16+ monocytes, CD8+ T lymphocytes, sIL-2R, autoantibodies and miRNA), 
with a further subdivision into cellular and soluble biomarkers. It becomes clear that, until 







CRPS, however, there are a number of promising biomarkers that warrant investigation in 
future research.
Chapter 4 - elevated plasma levels of sIL-2R in Complex Regional Pain 
Syndrome: a pathogenic role for t-lymphocytes?
Not much is known about the role of T cells in the onset and maintenance of CRPS. In this 
retrospective cohort study, we evaluated T cell activity in CRPS by comparing blood soluble 
interleukin-2 receptor (sIL-2R) levels between CRPS patients and healthy controls. Soluble 
IL-2R is a marker for T cell activity and has been shown to be increased in diseases in which 
T cell activity is centrally involved, such as rheumatoid arthritis and sarcoidosis. CRPS 
patients had statistically significant higher levels of sIL-2R than those of healthy controls. 
Furthermore, sIL-2R level was found to be a good discriminator between CRPS patients 
and healthy controls with a high sensitivity and specificity. The findings from this chapter 
indicate increased T cell activity in CRPS patients suggesting a possible T cell mediated 
inflammatory disease process. Furthermore, this chapter introduces sIL-2R as a potential 
diagnostic biomarker in CRPS.
Chapter 5 - Serum soluble interleukin-2 receptor does not differentiate 
Complex Regional Pain Syndrome from other pain conditions in a 
tertiary referral setting
In this prospective cohort study, we explored whether sIL-2R could be used as a diagnostic 
marker in CRPS. To this end, sIL-2R levels were determined in patients who were referred 
to our pain center with a suspicion of CRPS. Subsequently, sIL-2R levels of the patients 
diagnosed with CRPS were compared with sIL-2R levels of the patients who were not 
diagnosed with CRPS. Soluble IL-2R levels of healthy volunteers were used as controls. The 
study confirmed the findings in Chapter 4: sIL-2R levels of CRPS patients are higher than 
those of healthy controls. Soluble IL-2R could not, however, be used to distinguish CRPS 
patients from patients with other pain conditions of a limb which were initially suspected 
to have CRPS. However, this does not exclude its use in monitoring inflammatory disease 
activity in CRPS; this should be explored in future research.
Chapter 6 – elevated serum soluble CD163 indicates macrophage 
activation in Complex Regional Pain Syndrome
Various findings point towards activation of the monocyte-macrophage system in CRPS. For 
example, TNF-α, which is primarily released by local pro-inflammatory M1 macrophages, 
has been shown to be increased in blister fluid of affected CRPS extremities and increased 
levels of circulating pro-inflammatory CD14+CD16+ monocytes have been found in venous 
blood of CRPS patients. Furthermore, immunomodulating medication such as thalidomide, 




















cells, seem to be effective in certain CRPS cases. Therefore, exploration of this system is 
warranted in CRPS as this system could be an interesting target for future therapies. To this 
end, in this retrospective cohort study, levels of the macrophage-specific soluble CD163 
(sCD163) receptor were measured in CRPS patients and compared with sCD163 levels 
of healthy controls. The study revealed sCD163 was significantly higher in CRPS patients 
than in healthy controls, suggesting activation of local tissue-resident macrophages, and 
by extension the monocyte-macrophage system, in CRPS. Future studies should focus on 
exploring whether this marker can be used to diagnose CRPS, whether this marker can be 
used to monitor disease activity in CRPS, and whether this marker can be used to select 
therapies targeting monocytes/macrophages in CRPS.
Chapter 7 – Denying the truth does not change the facts: a systematic 
analysis of pseudoscientific denial of Complex Regional Pain Syndrome
Several articles have claimed that CRPS not exist. These articles not only undermine current 
empirical evidence that suggests otherwise, but also could potentially harm patients by en-
couraging dismissal of their signs and symptoms. In this chapter, we conducted a systematic 
literature search to evaluate the methodological quality of articles that claim CRPS does not 
exist. We then examined and refuted the arguments supporting this claim using up-to-date 
scientific literature on CRPS. Four narrative reviews, 2 personal views, 1 letter, 1 editorial 
and 1 case report were identified and included in this review. We identified seven points 
of controversy that were used in these articles to argue that CRPS does not exist: 1) the 
label ‘CRPS’; 2) the ‘unclear’ pathophysiology; 3) the validity of the diagnostic criteria; 4) 
CRPS as a normal consequence of immobilization; 5) the role of psychological factors; 6) 
other identifiable causes for CRPS symptoms; and 7) the methodological quality of CRPS 
research. We concluded that the level of evidence for the claim that CRPS does not exist 
is very weak. Furthermore, most arguments could be refuted by the extensive empirical 
literature on CRPS.
Chapter 8 - General discussion
In the final chapter of this thesis, the general discussion, the findings from this thesis are 
summarized and discussed in a broader context, i.e., in terms of clinical and research applica-
tion. Recommendations are made for future research on biomarkers in CRPS. It is important 
to note that although this thesis was focused on biomarkers of inflammation in CRPS, the 
pathophysiology of CRPS is complex and consists of multiple mechanisms. Therefore, it is 
likely that there will never be one biomarker or diagnostic test specific for CRPS, rather, it 
is imaginable that in the future a panel of diagnostic biomarkers or tests will be used to not 
only diagnose CRPS, but also to identify which pathophysiological mechanisms are involved 








hoofdstuk 1 - General introduction
Hoofdstuk 1 bespreekt de achtergrond en het doel van dit proefschrift welke in grote lijnen 
zijn: 1) de noodzaak van biomarker-onderzoek in Complex Regionaal Pijn Syndroom 
(CRPS) benadrukken en 2) het aanpakken van de huidige scepticisme over het bestaan  van 
dit syndroom. CRPS wordt nog steeds gediagnosticeerd aan de hand van relatief subjectieve 
klinische criteria en er is nog geen objectieve test beschikbaar om deze ziekte te diagnosticeren. 
Deze subjectiviteit leidt niet alleen tot een vertraging bij de diagnose, maar ook tot scepsis 
over het bestaan  van dit syndroom; beide kunnen schadelijk zijn voor patiënten die aan deze 
aandoening lijden. De identificatie van diagnostische (en therapeutische) biomarkers bij 
CRPS zou niet alleen een objectieve component toevoegen aan het diagnostische proces van 
CRPS, maar ook eerdere identificatie en behandeling van dit syndroom vergemakkelijken. 
Hoewel de exacte pathofysiologie van CRPS nog moet worden onderzocht, wordt momen-
teel  algemeen aangenomen dat inflammatie een belangrijk mechanisme is, niet alleen bij 
het ontstaan, maar ook bij het in stand houden van CRPS. Daarom is inflammatie een 
interessante ‘target’ voor biomarker-onderzoek bij CRPS en wordt de rol van inflammatoire 
biomarkers, vooral voor T-cel- en lokale macrofaagactiviteit, bij de diagnose en behandeling 
van CRPS onderzocht.
hoofdstuk 2 - Complex Regional Pain Syndrome: diagnosis and 
treatment
In dit hoofdstuk wordt een beknopt overzicht gegeven van de huidige inzichten over de 
pathofysiologie van CRPS en worden de huidige aanbevelingen voor het stellen van de 
diagnose en behandeling van CRPS besproken. Pathofysiologische mechanismen die aan 
de orde komen zijn inflammatie, neurogene inflammatie, auto-immuniteit, ischemie-
reperfusieletsel, genetische betrokkenheid, corticale reorganisatie, dunne vezel neuropathie 
en psychologische factoren. De hoekstenen voor diagnose, namelijk anamnese en lichame-
lijk onderzoek, worden besproken. De aanbeveling is om de behandeling van CRPS op 
een mechanism-based manier uit te voeren, m.a.w. op basis van de actieve onderliggende 
pathofysiologische mechanismen. Behandelingen die aan bod komen zijn ontstekingsrem-
mers, analgetica/co-analgetica, vaatverwijders, spierverslappers/spasmolytica, psychologische 
interventie en invasieve behandelingen.
hoofdstuk 3 - highlighting the role of biomarkers of inflammation in 
the diagnosis and management of Complex Regional Pain Syndrome
In dit hoofdstuk wordt de rol van inflammatie in de (multi-mechanisme) pathofysiologie 
van CRPS besproken en wordt de toepassing van mogelijke biomarkers van inflammatie 




















onderverdeeld in lokale biomarkers (TNF-α, IL-6, Tryptase, Mestcel aantallen) en systemi-
sche biomarkers (CGRP, SP, CD14 + CD16 + monocyten, CD8 + T lymfocyten, sIL-2R, 
auto-antilichamen en miRNA), met een verdere onderverdeling in cellulaire en oplosbare 
(soluble) biomarkers. Het wordt duidelijk dat er tot op heden nog geen biomarker is geva-
lideerd voor gebruik bij de diagnose en behandeling van CRPS, maar er zijn wel een aantal 
veelbelovende biomarkers die in toekomstig onderzoek onderzocht zouden moeten worden.
hoofdstuk 4 - elevated plasma levels of sIL-2R in Complex Regional 
Pain Syndrome: a pathogenic role for t-lymphocytes?
Er is niet veel bekend over de rol van T-cellen bij het ontstaan en in stand houden van CRPS. 
In deze retrospectieve cohortstudie hebben we T-celactiviteit bij CRPS geëvalueerd door 
de waarde van de soluble interleukine-2-receptor (sIL-2R) in bloed te vergelijken tussen 
CRPS-patiënten en gezonde controles. Soluble IL-2R is een marker voor T-celactiviteit en 
het is aangetoond dat deze marker verhoogd is bij ziekten waarbij T-celactiviteit een centrale 
rol speelt, zoals bij reumatoïde artritis en sarcoïdose. CRPS-patiënten hadden statistisch sig-
nificante hogere waarden van sIL-2R vergeleken met die van gezonde controles. Daarnaast 
bleek het sIL-2R-gehalte een goede discriminator te zijn tussen CRPS-patiënten en gezonde 
controles met een hoge sensitiviteit en specificiteit. De bevindingen uit dit hoofdstuk duiden 
op een verhoogde T-celactiviteit bij CRPS-patiënten, wat een mogelijke T-cel gemedieerd 
ontstekingsproces zou betekenen. Verder bespreekt dit hoofdstuk sIL-2R als een potentiële 
diagnostische biomarker bij CRPS.
hoofdstuk 5 - Serum soluble interleukin-2 receptor does not 
differentiate Complex Regional Pain Syndrome from other pain 
conditions in a tertiary referral setting
In deze prospectieve cohortstudie hebben we onderzocht of sIL-2R kan worden gebruikt als 
diagnostische marker bij CRPS. Hiervoor zijn de sIL-2R-waarden bepaald bij patiënten die 
met verdenking op CRPS naar ons pijncentrum waren verwezen. Vervolgens werden de sIL-
2R-waarden van de patiënten met de diagnose CRPS vergeleken met de sIL-2R-waarden van 
de patiënten bij wie de diagnose van CRPS niet werd gesteld. Soluble IL-2R-waarden van 
gezonde vrijwilligers werden als controles gebruikt. De studie bevestigde de bevindingen uit 
hoofdstuk 4: de sIL-2R-waarden van CRPS-patiënten zijn hoger dan die van gezonde con-
troles. Soluble IL-2R kon echter niet worden gebruikt om CRPS-patiënten te onderscheiden 
van patiënten met andere pijnaandoeningen van een ledemaat waarvan aanvankelijk werd 
vermoed dat ze CRPS hadden. Deze bevinding sluit echter het gebruik van deze marker bij 
het monitoren van inflammatoire ziekteactiviteit bij CRPS niet uit. Dit zal in toekomstig 







hoofdstuk 6 – elevated serum soluble CD163 indicates macrophage 
activation in Complex Regional Pain Syndrome
Er zijn diverse aanwijzingen voor activering van het monocyt- en macrofaagsysteem bij 
CRPS. Zo is TNF-α, dat voornamelijk wordt geproduceerd door lokale pro-inflammatoire 
M1-macrofagen, verhoogd in blaarvocht van aangedane CRPS-extremiteiten en zijn ver-
hoogde niveaus van circulerende pro-inflammatoire CD14+CD16+-monocyten in veneus 
bloed gevonden van CRPS-patiënten. Bovendien lijken immuunmodulerende medicijnen 
zoals thalidomide, die een deel van zijn effecten op monocyten uitoefent en daardoor de 
productie van TNF-α door deze cellen vermindert, effectief te zijn in sommige CRPS-pati-
ënten. Onderzoek doen naar de activatie van dit systeem bij CRPS lijkt dan ook van belang, 
aangezien dit systeem een  interessante target zou kunnen zijn voor toekomstige therapieën. 
In deze retrospectieve cohortstudie werden de waarden van de macrofaag-specifieke soluble 
CD163 (sCD163) receptor gemeten bij CRPS-patiënten en werden deze vergeleken met 
sCD163-waarden van gezonde controles. De studie liet zien dat sCD163 significant hoger 
was bij CRPS-patiënten dan bij gezonde controles, wat duidt op activering van lokale weef-
sel-macrofagen, en dus het monocyt- en macrofaagsysteem bij CRPS. Toekomstige studies 
zouden zich moeten richten op het onderzoeken of deze marker kan worden gebruikt om 
CRPS te diagnosticeren, of deze marker kan worden gebruikt om ziekteactiviteit bij CRPS 
te monitoren en of deze marker kan worden gebruikt om therapieën gericht op monocyten 
en macrofagen te selecteren. 
hoofdstuk 7 – Denying the truth does not change the facts: a systematic 
analysis of pseudoscientific denial of Complex Regional Pain Syndrome
In verschillende artikelen wordt beweerd dat CRPS niet bestaat. Deze artikelen ondermijnen 
niet alleen het huidige empirische bewijs dat anders suggereert, maar kunnen patiënten 
mogelijk ook schaden door (para)medische specialisten aan te moedigen de CRPS tekenen 
en symptomen van patiënten te negeren. In dit hoofdstuk hebben we een systematisch lite-
ratuuronderzoek uitgevoerd om de methodologische kwaliteit van artikelen die claimen dat 
CRPS niet bestaat te beoordelen. Vervolgens hebben we de argumenten die deze bewering 
ondersteunen onderzocht en weerlegd met behulp van actuele wetenschappelijke literatuur 
over CRPS. Vier narrative reviews, 2 personal views, 1 letter, 1 editorial artikel en 1 case 
report werden geïdentificeerd en opgenomen in deze review. We identificeerden zeven hoofd-
argumenten die in deze artikelen werden gebruikt om te beweren dat CRPS niet bestaat: 1) 
het label ‘CRPS’; 2) de ‘onduidelijke’ pathofysiologie; 3) de geldigheid van de diagnostische 
criteria; 4) CRPS als normaal gevolg van immobilisatie; 5) de rol van psychologische factoren; 
6) andere aanwijsbare oorzaken van CRPS-symptomen; en 7) de methodologische kwaliteit 
van CRPS-onderzoek. We concludeerden dat het bewijsniveau (level of evidence) voor de 
bewering dat CRPS niet bestaat, erg zwak is. Bovendien konden de meeste argumenten 
worden weerlegd met behulp van de uitgebreide empirische literatuur over CRPS.
hoofdstuk 8 – General Discussion
In het laatste hoofdstuk van dit proefschrift, de general discussion, worden de bevindingen 
uit dit proefschrift samengevat en besproken. Er worden aanbevelingen gedaan voor toekom-
stig onderzoek naar biomarkers bij CRPS. Alhoewel dit proefschrift zich met name richt op 
inflammatoire biomarkers bij CRPS, is het belangrijk op te merken dat de pathofysiologie 
van CRPS complex is en bestaat uit meerdere mechanismen. Het is hierdoor aannemelijk 
dat er nooit één biomarker of diagnostische test specifiek voor CRPS zal zijn, maar dat 
er in de toekomst een panel van diagnostische biomarkers of tests zullen worden gebruikt 
om niet alleen CRPS te diagnosticeren, maar ook om te bepalen welke pathofysiologische 















Here it is then, my thesis. A product of hard work, fun, laughter, tears and unconditional 
support from friends, family and co-workers. So many people deserve so much credit for 
helping me get here. Although I know these (short) words of appreciation will never be 
enough to thank all of you, I hope that each and every one of you understands  how special 
and dear you are to me and that without your support, I would not be here. 
So here goes (yes, I’m about to mix all the languages I know),
First, I’d like to thank the people that directly contributed to the making of this thesis:
I’d like to start by thanking my promotor/supervisor Prof. dr. f.J.P.m. huygen. Beste 
Frank, het voelt als gisteren dat ik mijn eerste kennismakingsgesprek bij jou had in het kader 
van mijn masteronderzoek en ik weet nog dat ik erg blij was toen ik te horen kreeg dat ik 
mocht blijven als promovenda. Wat had ik ook geluk dat jij Maaike hebt gekozen als mijn 
co-promotor. De tijd is enorm snel gegaan. Bedankt voor de fijne begeleiding, de gezellige 
tweewekelijkse afspraken die Anita altijd moest onderbreken (haha), en met name voor de 
steun door de leuke en wat minder leuke tijden van mijn promotietraject. Ik vind het een eer 
om bij de afdeling Pijngeneeskunde te hebben mogen promoveren en ik kijk er naar uit om 
verder onderzoek te blijven te doen (als je maar mijn roei-verhaal niet aan alle beginnende 
promovendi vertelt!). 
Next, my co-promotor/co-supervisor dr. m. Dirckx. Lieve Maaike, lieve co-promotor, 
ik zeg het nogmaals: wat een GELUK heb ik gehad met jou als co-promotor. Het is alsof de 
professor wist dat wij allebei van Kletsen en Koreaans hielden en dus bij elkaar had gezet. 
Wat hebben wij een fijne tijd met elkaar gehad: onderzoek doen, borrelen, Koreaans eten, 
kletsen onder het genot van cappuccino’s en kaascroissantjes – ik mis je nu al. Zonder jou 
was dit proefschrift NOOIT gelukt. Jij bent mijn mental support pillar geweest voor dit 
hele traject. Weinig mensen kunnen zeggen dat ze hun co-promotor dag en nacht mochten 
bellen bij mental breakdowns. Ik heb je al eerder in real life verteld dat deze woorden nooit 
echt recht zullen doen aan hoe dankbaar ik ben om jou te hebben mogen leren kennen and 
to have you in my life, I am forever grateful. PS: je komt nooit meer van me af! 
I’d further like to thank dr. W.a. Dik for helping me with all the immunological aspects 
of this thesis. Beste Wim, bedankt voor jouw intensieve begeleiding en geduld tijdens mijn 
promotietraject. Jij nam altijd de tijd om alles zo uitgebreid mogelijk aan ons uit te leggen 
en zonder jou expertise was dit proefschrift zeker niet gelukt. Ik ben je enorm dankbaar. 
I’d like to thank dr. D.L. Stronks. Lieve Dirk, doctor Stronks, our nutty professor. Dirk, 
het was echt een genoegen om met jou samen te werken. Bedankt voor al jouw hulp bij de 







het proefschrift, het leven en semantiek. Wij konden ons uren bezig houden met waarom een 
zin grammaticaal wel of niet klopte in het Engels en hoe het kon dat iets methodologisch 
correct opschrijven niet altijd het begrip van de tekst bevorderde. Maar goed, we kwamen er 
altijd samen uit. Another topic we loved discussing: your sense of direction. Maar daar zal 
ik hier niet op in gaan, iedereen weet waar ik het over heb haha! Bedankt lieve Dirk. Geniet 
van jouw pensioen!
I’d further like to thank Prof. dr. R.J. Stolker. Beste Robert Jan, bedankt voor de mo-
gelijkheden die gecreëerd werden zodat ik tijdens mijn eerste 3 maanden van mijn opleiding 
mijn proefschrift kon afronden. Ik vind het een eer dat mijn opleider zitting neemt in mijn 
commissie. 
I’d also like to thank Dr. m. Klimek. Beste Markus, bedankt voor de veilige sfeer die 
gecreëerd wordt voor ons als (beginnende) AIOS. Ik kijk uit naar een fijne opleidingstijd. 
A big thank you goes to anita van toor: Lieve Anit, jij bent echt m’n maatje en m’n 
confidant geweest tijdens (en ook na) mijn promotietraject. Zonder even met jou gekletst te 
hebben iedere ochtend, kon mijn dag niet goed van start gaan. Ik kon bij jou altijd mijn hart 
luchten, maar ook zaken doen. Bedankt voor jouw hulp, steun en vriendschap gedurende 
deze jaren. I hold you dear to my heart and hope we will always be friends. Hopelijk kunnen 
we met z’n allen ook snel weer een rondje Valencia doen!
Next, everyone that contributed indirectly, but just as importantly, to the making of this 
thesis:
First, I’d like to thank all my colleagues from the pain department for their support over the 
years. 
I’d like to start by thanking heike Buda, who I hold very dear to my heart. Lieve Heike, 
ik weet nog steeds niet hoe wij zo close zijn geworden, maar wat ben ik blij om jou in mijn 
leven te hebben. Zonder jou, had ik mijn tijd op de pijn ook nooit overleefd (hoe wij de 
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en Anita ben jij onderdeel van mijn pijnfamilie geworden. Thank you for your kindness, 
friendship and guidance. I’ll never forget how you and Paul got everyone together for my 
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I’d like to thank all my PhD colleagues starting with the “original crew”: Nadia, Catel-
ijne, Johan, mariska and Judith. Guys, thank you all for the laughs and unconditional sup-
port throughout the years. Lieve Naad, met jou kon ik altijd lachen, roddelen, en vooral over 
onze ‘allochtone’ dingen hebben, bedankt voor het lieve welkom op de pijngeneeskunde (op 
de gang...). Lieve Caat, ondanks dat wij maar kort samen een kantoortje hebben gedeeld, 
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steun en discretie, ik weet dat ik altijd in volle vertrouwen mijn verhaal aan jou kwijt kon. 
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bedankt voor de fijne samenwerking. Lieve Bart, ook wij hebben maar kort samenwerkt, 
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thank Cecile de vos. Lieve Cecile, onze koffiemomentjes en vegetarian dinners waren altijd 
een fijne onderbreking van de phd-stress. Bedankt voor jouw lieve woorden en steun. 
I’d like to further thank emmy van Bodegraven. Lieve emmy, over de jaren heen heb-
ben wij leuke en minder leuke tijden meegemaakt. Gelukkig konden wij samen altijd om 
alles lachen. Bedankt voor jouw steun tijdens mijn promotietraject. Jij hield alles goed in de 







worden. Protocollair werken, heb ik van jou geleerd. Emmy, na de nieuwbouw hebben we 
elkaar door de afstanden weinig gezien, maar gelukkig kon ik nog wel bij jouw afscheids-
feestje aanwezig zijn om jou een fijn pensioen toe te wensen. 
Next, I’d like to thank all my supervisors that supported me throughout the years: 
Sander frankema, Lot Bosman, evelyn Thung. Beste Sander, I have only one thing (or 
maybe 4) to say: “sugar, sugar, sugar, sugar”. Bedankt voor jouw steun en gezellige speeches 
en integratiecursussen op de vrijdagochtenden. Lieve Lot, jij hebt altijd een luisterend oor 
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Bedankt voor jouw lieve woorden en steun over de jaren heen. 
Of course, I’d like to thank the “Ladies of the Balie”: Rebecca, astrid, margreet, Co-
rine. Lieve allen, bij jullie konden we na een dagje poli even komen lachen. Lieve Rebec, 
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I’d like to start by thanking my Curaçao crew: marchena, arthur and Gigi. Guys, some-
times I wonder how time flew by so fast: one minute we were sitting by the benches by the 
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best. I’m grateful for our friendship. Thank you for always being there for me.
My PhD girls: Dina, Stephanie and Nermina. Onze koffiemomentjes bij de Doppio 
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